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Sm^ M^ VRY
There is sufficient evidence to show that the kinetics of 
thyroidal uptake of iodide in man can normally be described in terms of 
an open three-compartment binding model. Tlie parameters of this model 
Consist of a unidirectional clearance of iodide from the plasma 
compartment into the iodide compartment of the gland, an exit rate 
constant describing return of iodide to plasma, and a binding rate 
constant describing incorporation of iodide into the bound iodine 
compartment. In the event of there being complete absence of binding, 
the bound compartment and binding rate are ignored.
Published work with radioactive tracers has produced fairly 
consistent results as far as unidirectional clearance and exit rate 
are concerned, but there is considerable variance in the binding 
rate estimates for iodide. Values for the latter in the uninhibited 
gland have varied by almost two orders of magnitude; namely, from 
being similar in magnitude to the exit rate, to being much greater. A 
probable explanation for this discrepancy, however, is to be found in 
recent work where tracer levels in arterial plasma (which are greater 
at early times) were applied in the analysis rather than levels in 
venous blood. In these circumstances the net clearance of tracer 
into the gland was found to be constant with time, suggesting that the 
binding rate is normally much greater in magnitude than the exit rate.
A new "least sum of squares" analysis of kinetic uptake data,
Which incorporates a correction for arterio/venous differences in 
tracer levels, is described in this thesis. The method is based on the
—  14 —
open three-!compartment binding model of the gland and assumes intiavenous 
administration of the tracer; radioactivity levels in thyroid and plasma 
being monitored for a period of 60 minutes following administration of 
the tracer. No constraints are imposed on the parameters of the 
model but a further parameter, initial free upi^ke, is introduced to 
allow for uncertainty in plasma tracer levels immediately after 
Injection, The use of the latter parameter also compensates for 
rapid early reduction in clearance due to protein binding of the tracer 
in plasma, A computer programme was written to provide estimates of 
the various parameters and the associated random errors. An analysis 
of the uptake changes after a blocking dose of perchlorate is also 
described which provides a means of verifying results from the uptake 
phase, (Empirical studies revealed also that an estimate of binding 
rate could be obtained from the fraction of uptake discharged by 
perchlorate).
When the new method of analysis was applied to radioiodide uptake 
data from normal and untreated thyrotoxic subjects, neither exit nor 
binding rate could be satisfactorily determined. The results were 
consistent with theoretical predictions as to the problems that might 
arise if the binding rate were much greater than the exit rate. Thus 
it was concluded thatpWhen the binding function of the gland is not 
inhibited by drugs or disease, the binding rate of iodide is normally 
greater than the exit rate.
Further support for a relatively high binding rate was found in 
the results of perchlorate discharge studies in a number of untreated 
thyrotoxic subjects. Even at early times after administration of the 
radioiodide, there was only one subject in whom a significant discharge
— 15 —
of radioiodide vas observed. (Other published work in normal and 
Untreated thyrotoxic subjects also reveals a similar virtual absence 
of free radioiodide in the uninhibited gland).
The finding of a small discharge in one untreated thyrotoxic 
subject did, however, permit a lower limit of 0.150 minute”'^ to be 
estimated for the binding rate of iodide in the uninhibited gland*
Studies in subjects given antithyroid drugSjOr in subjects with binding 
defects, provided an estimated mean value (tsd) of 0,046-0.031 minute"^ 
for the exit rate. Consideration of the steady state equations of the 
model revealed that with these estimates, the effective clearance of 
iodide into the gland is normally 75-100% of the unidirectional clearance, 
Unidirectional clearance of iodide was found to be dependent upon 
thyroid status, the mean value (isd), 160.7^138.5 ®1 minute"^, in 
thyrotoxic subjects being greater than the mean value, 23.1^9 ,5 ml 
minutely in normal subjects.
Both unidirectional clearance and exit rate of pertechnetate were 
found to be linearly related to the corresponding parameters for 
iodide. However.whilst the exit rate for pertechnetate was greater, 
the unidirectional clearance was less than that for iodide, A mean 
value («sd) of 0,001*0.003 minute"! was found for the binding rate of 
pertechnetate In normal and thyrotoxic subjects.
The new method of analysis was applied to serial uptake data of 
radioiodide and 99m^^_pgrtechnetate in thyrotoxic subjects being 
treated routinely with antithyroid drugs. No clear association was 
found between the parameters of the model and the final outcome of 
therapy. However it was demonstrated that^on occaslonSylack of response 
to these drugs can be due to a lower than normal exit rate of iodide
- 16 -
rather than failure of the drug to effectively reduce binding rate.
In these circumstances the effective clearance of iodide remains 
relatively high.
The occasional observation of uptake values of pertechnetate 
that exceed those of Iodide, during drug therapy, vas found to be 
due to there being greater intial free uptake of the former. Initial 
free uptake, which langed from 0-18 % dose for iodide and 0-24 % dose 
for pertechnetate, was considered to reflect the inherent affinity of 
the gland for a specific anion, before any plasma binding has time to 
be completed. The results supnort published work on the fundamental 
properties of anions which suggests that the affinity for pertechnetate 
should be greater than that for iodide. Initial free uptake was 
found to increase as the symptoms of thyrotoxicosis were suppressed 
by the action of the antithyroid drug. This is what would be expected 
if initial free uptake were a measure of the fraction of the injected 
tracer bolus that is trapped by the thyroid, with the knowledge that 
cardiac output, but not thyroidal blood flow, is reduced by drug 
action.
Studies of untreated thyrotoxic subjects, and of subjects who 
had completed antithyroid drug therapy, revealed no increased incidence 
of defective binding in the latter group. This would suggest that 
antithyroid drugs have no long-term effect on iodide binding. In 
one treated thyrotoxic subject who did manifest defective binding after 
therapy, it was finally proven that antithyroid drugs were being taken 
surreptitiously, A small persistent defect was found in another 
treated thyrotoxic subject but no clear association between the defect
— 17 —
and previous drug treatment could be established.
The new method of analysis was found to be valuable in quantifying 
the effect of different dosages of antithyroid drug in the short-term. 
Untreated thyrotoxic subjects were placed on specific dosages of 
carbimazole in the range 5 mg d“  ^to 40 mg d"T for consecutive periods 
of one week, A radioiodide uptake study was performed at the end of 
each week*s treatment with a given drug dosage, üh most cases there 
was little to be gained, in terms of reduction in binding rate and 
effective clearance of iodide, by increasing drug dosage beyond 
10 mg
Subjects with iodination defects were also investigated with the
object of quantifying the defect by kinetic analysis, Tliis also
provided an opportunity of checking the predictions of the analysis, 
against the observations after perchlorate, for a range of binding 
rates. The results indeed confirmed the reliability of the new
method of analysis. Binding rate of iodide in the subjects ranged
from 0,0-0.091 minute“ ^ and effective clearance of iodide from 0-68% 
of the unidirectional clearance, l-Jhen the effective clearance was 
greater than 60% there were no biochemical nor clinical signs of 
thyroidal disease. There was good correlation between the effective 
clearance of iodide in absolute teimis (i.e. ml minute” ^) and the 
residual uptake after perchlorate. This might prove to be a simple 
method of assessing the degree of replacement therapy in subjects 
with defective binding.
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CHAPTER ONE
MODELS AND ANALYSIS OF ANION UPTAKE BY THE 
THYROID GLAM) IN MAN - A REVIEW OF PREVIOUS WORK.
1,1 Introduction
The thyroid gland has the ability to concentrate several different 
anions of which iodide and pertechnetate have been studied widely in 
radioactive tracer form (1, 2), Included also are the thiooyanate and 
perchlorate ions but these are best known for their action, when 
administered in pharmacological doses, as inhibitors of thyroidal uptake 
(l). The common features linking these ions are physical rather than 
chemical, thyroidal concentration being determined by ionic size, shape 
and charge rather than by place in the Periodic table of elements (l). 
Iodide is unique, however, in that concentration of the ion is only the 
first stage in its utilisation for physiological purposes. Whilst there 
may be some metabolism and binding of the other ions trapped by the thyroid 
(1, 3-7) these have no known role in the natural function of the gland.
Thyroidal concentration of iodide (and other ions) involves 
initially an active transport mechanism (l, 8, 9). An ion pump transports 
iodide from the blood to the thyroid cells through the basal membrane, 
but subsequent movement of iodide from cell to lumen through the apical 
membrane is probably not the result of an active process but simply the 
result of an existing electrical gradient (2). At this stage the trapped 
ion is still freely exchangeable with iodide in plasma. However it is
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soon oxidised and bound to thyroglobulin where it appears within minutes 
as monoiodotyrosine and diiodotyrosine, and later, by coupling of these 
two tyrosines, as triiodothyronine (T3) and thyroxine (T4) (9-11)#
After a variable period of storage the bonds to thyroglobulin are broken 
resulting in T3 and T4 being released as active hormones into the 
circulation. Some newly formed hormone may leave the gland within 2 hours 
(II-I3), but the biological half period of intra-thyroidal hormone ranges 
from 7-164 days in normal subjects (ll). Iodide produced by the 
peripheral degradation of T3 and T4 is available for recycling through the 
thyroid.. Tliere is also some intra-thyroidal deiodination of organic 
material producing an additional iodide pool, but this is functionally 
separate from that derived by active transport (l, 9, 14).
1 ,2  Models of the Thyroid Gland,
Various models have been devised to describe the complete iodine 
cycle in humans. The simplest model has three compartments - an 
inorganic iodide'pool which includes iodide within the thyroid, and two 
pools of organic iodine, one within the thyroid and the other comprising 
all extra-thyroidal organic iodine (15-16). There are additional 
compartments in more elaborate models which have been constructed to 
cover all aspects of thyroid function (17-20), including regulation of 
thyroid function by endogenous and exogenous agents (21-22), In practice 
the main application of these models has been in the analysis of tracer 
data over intervals extending to 50 days after administration.
Generally there has been good agreement between the predictions of these 
models and experimental data, thus allowing the evaluation of parameters 
which are useful indices of thyroid function.
- 20
The present work, however, is not concerned with the complete 
iodine cycle, but only with the early stages. It covers the initial 
accumulation of inorganic iodide from the blood (trapping) and 
subsequent organification (binding) of trapped iodide within the thyroid, 
up to the time before any substantial release of organified iodine 
occurs. For the purposes of analysing the variation in early uptake of 
a radioactive tracer by the thyroid, it is customary to describe the 
interaction between thyroid and blood in terms of compartmental models.
In the models described by Larsson (23), and tollman and Reed (24-26), 
which are known as "open" compartment models, the size of the plasma 
iodide pool is not strictly defined. Transport of ion into the gland 
is expressed as the product of plasma iodide concentration and 
unidirectional clearance of the ion from plasma.
Alternatively the plasma pool may be strictly defined and hence 
the use of "closed" compartmental models such as those described by Rail 
et al (17) and Berman (20). The work of Berson and Yalow (12) was also 
essentially based on the "closed" compartment concept of the plasma 
iodide pool. Transport of iodide into the gland is the product of a 
transfer late constant and the total iodide in the plasma compartment.
In practice, evaluation of the latter parameter requires the additional 
measurment of plasma volume which makes the "closed" compartment models 
less convenient to apply. However, for the purpose of comparing results 
of various studies of tracer kinetics, it is a straightforward matter to 
reduce the parameters of the "closed" compartment models to the form of 
those in the "open" compartment type, using the expression;- 
transfer rate constant x plasma volume = unidirectional clearance,
Wolff (l) and Robertson (27) have reviewed the application of "open" 
compartment models. There are four models in all (Figure l.l), two
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Figure 1,1 Compartmental models of iodide uptake by the thyroid 
gland. Except for the arrow labelled "C", representing 
unidirectional clearance of iodide from plasma, arrows represent 
rate constants of iodide transfer between the appropriate 
compartments.
for use when there is no intra-thyroidal binding and the other two for 
application when there is significant binding. All the models allow 
for return of unbound iodide to plasma. The basic difference within 
each pair is that one model has only a single iodide compartment within 
the thyroid whilst the other has two compartments, which represent 
separate iodide pools in the cells and lumen.
Robertson (2?) has reviewed the more recent literature on the 
distribution of radioiodide within the thyroid and concluded that, except 
in the case of the hypothyroid gland, a concentration gradient between 
the lumen and cells is rapidly established. (From a review of the 
literature and from his own studies Gray (28) has shown that the same is 
true for the pertechnetate ion), This means that the rate constant of 
flow into the lumen is much greater than the exit rate. Thus the 
mathematical equations describing the models with two iodide compartments 
can be simplified to the form of those with a single intra-thyroidal iodide 
compartment (l) and, as far as external measurements of early thyroid 
uptake are concerned, it would be impossible to distinguish two pools of 
unbvund tracer. As a consequence, published analyses of the early stage 
of ion input to the gland have not^usually, advanced beyond the single 
iodide compartment models of Figure 1.1, It must be noted that the 
sophisticated model of human iodine metabolism described by Degroot et al 
(19) has two iodide pools, but the additional pool is to account for 
degradation within the thyi'oid of previously organified iodine,
1.3 General Consideration of Methods
Because there are a number of suitable radioisotopes of iodine
123 131 132
( I> I and I), in vivo studies of ion uptake by the human thyroid
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gland may be performed conveniently using radioactive tracers (27),
Pertecbnetate-^^^Tc has also been used in the study of ion transport 
and Wolff in his recent review (2) has discussed the reasons for this.
In the first instance pertechnetate shares many of the transport 
properties of iodide, although binding of the ion is minimal. It is 
accumulated by all the organs known to accumulate iodide (the thyroid 
and salivary glands, the choroid plexus, the gastric mucosa^etc.),
It shares the same active transport process as iodide and other ions, and 
is displaced by iodide. If the binding function of the gland is 
completely inhibited, the steady state concentrations of pertechnetate 
are of the same order of magnitude as those of iodide. Most of the 
pertechnetate accumulated by the gland is readily discharged by 
pharmacological doses of perchlorate and thus the ion behaves as iodide 
when binding is blocked. Secondly, the radioisotope ^^^Tc has favourable 
characteristics for in vivo studies. The photon energy is relatively 
low (14S KeV) and the radiation is readily collimated. Furthermore, the 
radiation dose to subjects is minimal (27) because of the short physical 
half-life (6 hours).
There have been several studies of the kinetic behaviour of ion 
uptake by the human thyroid gland using radioiodide (12, 16, 23, 29-40), 
^^^Tc - pertechnetate (41-46) or both (47—51) as tracers. Dual tracer 
investigations, involving the use of ^ 9mTc, facilitate study of the 
trapping function of the gland in the presence of binding. Studies 
have consisted of serial measurements of thyroid uptake following 
administration of the tracer using either an uptake counter, a radio­
isotope scanner or gamma camera (Chapter 4), combined with, in some cases 
serial measurements of plasma activity.
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In some of the earliest work, analysis of the experimental data 
consisted of plotting thyroid uptake against the square root of time 
(29). This facilitated clearer separation of the uptake curves for 
various thyroid states. More recent analysis has ranged from straight­
forward calculations of clearance (rate of change of thyroidal uptake 
divided hy tracer concentration in plasma), over various time intervals 
(16, 30, 32, 34-, 36-38, 53), to analysis in terms of compartmental models 
using graphical or computing techniques (12, 17, 20, 27, 28, 31, 39, 41,
4.9-52).
1.4. Estimation of Clearance and its Variation with Time.
After intravenous administration of 99mTo - pertechnetate, or of 
radioiodide when binding is inhibited, the net clearance of tracer from 
blood to thyroid is found to fall rapidly with time and may even become 
negative within the first hour (34-,41). This happens because, in the 
absence of binding, the tracer accumulated by the gland gradually returns 
to plasma, thus producing a falling uptake which eventually parallels 
the fall in plasma radioactivity.
Idien binding is allowed to continue as normal, the net'clearance 
of radioiodide has again been found to decrease with time. Initially, 
however, Berson and Yalow (12) found the clearance of radioiodide to be 
relatively constant over the period 4-80 minutes after intravenous 
administration of the tracer but Larsson (23) reported a falling clearance 
between 5-65 minutes in a proportion of patients. When uptake at earlier 
times is included a definite decrease in clearance is observed. Koutras
and Sfontouris (36) found that, in normal and thyrotoxic subjects, the 
2-20 minute clearance was greater than the 20-120 minute clearance and
24 —
suggested that the former represented the unidirectional clearance of 
iodide into the thyroid gland, Yamamoto, Moriya and Horiuchi (38) 
measured clearance in normal subjects at various times during the period 
0-120 minutes after tracer administration* The clearance from 0-4 minutes 
was found to be greater than that at later times and was taken to 
represent the unidirectional clearance, Degroot (l6) reported the 
clearance of radioiodide to decrease over the period 2-30 minutes in 
subjects with relatively active glands. Thereafter the clearance 
remained virtually constant for several hours after administration of the 
tracer. These observations of changing clearance at early times would 
suggest that there is significant return of iodide from thyroid to plasma, 
even when binding is preceding normally.
Another aspect of the phenomenon has been discussed by Shimmins 
et al (37) who showed that errors in measurement of uptake could seriously 
affect estimations of clearance. However, with more accurate evaluation
of extra-thyroidal activity (the main source of error in early uptake 
determination), the clearance from 2-20 minutes was still found to be 
greater than that from 20-120 minutes.
In the most recent investigation of these changes in early clearance 
of radioiodide, Gray et al (53) argued that thyroid cells would be exposed 
to a plasma concentration of tracer that approximates to that in arterial 
blood. Venous and arterial plasma concentrations were measured from 1 
minute onwards and it was found that arterial concentrations were 
significantly greater for the first 20 minutes after intravenous 
administration of the tracer (details are given in Section 3,2). When 
arterial plasma concentrations were applied to estimations of clearance, 
these arterial clearances were essentially constant from 2 minutes 
onwards. In effect these improved results suggest that, when binding is 
not inhibitec^  there is essentially no return of trapped iodide to blood 
perfusing the thyroid, i,e* the binding rate is much greater than the release
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rate of unbound iodide. The measured clearance is in fact the 
unidirectional clearance of tracer into the thyroid,
1,5■ Introduction to Compartmental Analysis
Whilst there are methodological differences amongst published 
analyses of early kinetic data using compartmental models, the results 
can usually be expressed in terras of the parameters of the "open" 
compartment models (Section 1,2). For ease of comparison these 
modifications will be made, whenever necessary, in the present review of 
published work. There is one exceptional method of analysis and that 
is the approach adopted by Esser et al (44) in their analysis of serial 
pertechnetate uptake data. Uptake curves were expressed as the sum of 
a constant and an exponential terra. This form of equation was based on 
earlier work on tracer theory (54). The constants of these equations 
cannot be related readily to the parameters of the "open" compartment 
models.
Before a detailed examination of published work is undertaken, it 
is worthwhile to consider the mathematical equations describing the 
transport of ion in those "open" compartment models which have a single 
iodide compartment. General comments can then be made about methods of 
■ solution using either graphical or computing techniques. For present 
purposes it is necessary to consider only the "open" three-corapartraent 
binding model (Figure 1.2),
Let C be the unidirectional clearance of tracer into the thyroid 
and Ip the plasma concentration at any time t. Loss from the pool of 
unbound tracer Up occurs by leakage back to plasma, represented by an 
exit rate constant Ktp, and by loss to the pool of bound tracer Up,
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Open three-compartment binding model of iodide uptake 
by the thyroid gland, C is the unidirectional clearance of iodide 
into the gland from plasma, K*fp is the exit rate constant of free 
iodide and Kg is the binding rate constant of free iodide into the 
bound iodine compartment.
represented by a rate constant Kg. If binding is blocked, i.e. Kg = 0, 
then
dUji/dt = C Ip - K^p Up (i)
A convenient way of solving for C and under this condition is 
to divide throughout by Ip and to plot (l/lp) (dUp/dt) versus Up/Ip. The
intercept on the axis of the former is C and the slope of the straight line 
is Kjp. One of the problems of this method is determining, precisely, the 
gradient of the thyroid uptake curve, dUp/dt, from the experimental data.
A graphical approach may be used which consists of fitting a curve, 
visually, through the uptake points and then drawing tangents to obtain 
estimates of the gradient at various times.
An alternative method of determining C and ICpp with Kg = 0 is to 
solve Equation 1 in the first instance for Up, If both sides of the 
equation are multiplied by e^ TP*'^  then,
a (U_. e%"b/dt = C Ip e
In order to avoid constraining the curve to pass through (0,0), thus 
allowing for experimental errors in determining tracer levels in plasma 
at very early times, another parameter may be introduced. Thus, as a 
boundary condition, let the computed curve pass through Up(T) at some 
time T (this can be taken as the time when precise determination of plasma 
levels becomes possible)• Therefore by integration
TJj,(t) = C e -Krp't Ip e%TP't dt + %(T) e-^ TpCt-T) (2)
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(This expression for uptake has been used by Newcomer (55)in animal 
studies and by Robertson (27) in human studies). The problem is thereby 
reduced to finding those values of the parameters C, and Up(T)
which produce a computed uptake curve that best fits the experimental data, 
This may be achieved using an analogue of digital computer.
It is interesting to note that the solution for Up(t) contains 
two components, the first representing the amount of tracer accumulating 
since time T, and the second, the amount of tracer still remaining due to 
the starting value Up(T),
If binding is not blocked, i.e. Kg ^ 0, then
dUp/dt — C Ip — KjipIIp — KpUp (3)
dUg/dt = KgUp (4)
d(upup/dt = c Ip _ KypUp (5)
Equation 5 can be re-arranged to yield.
Up = (CIp - d(Up Ug)/ dt)Arp (6)
If C and Kpp have been determined previously in a trapping study, i.e. 
with binding blocked by administration of an antithyroid drug, %  may 
be estimated by graphical methods (12), To do this, the slope of the 
observed uptake curve at various points is determined by drawing tangents, 
These values and the corresponding concentrations of tracer in plasma.
Ip, are substituted in equation 6 to provide estimates of at various
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times. The curve for organically bound tracer is obtained by subtracting
these estimates of U from the observed uptakes. Estimates of the
r
binding rate, Kg, may then be made from the slope of the bound tracer 
curve and the value for unbound tracer, Up at any given time. This 
follows from Equation 4 which can be re-arranged to yield
F
An alternative approach, which lends itself to curve fitting 
techniques using a computer, is to solve Equations (3) and (4) for Up 
and Ug, Applying the same boundary condition as before when binding 
was blocked, the solution for Up is
Up(t) = C ^ Ipe^Sp’*’ dt
. * V * - "  M
This expression for the quantity of tracer in the unbound pool at any 
time is essentially identical to that derived by Berman (20), It 
reduces to the earlier equation for U^ (t) when Kg = 0 (equation 2),
Again there are two components, the first representing the uptake since 
time T, and the second, the uptake remaining in the free compartment due 
to the starting value Ug(T), If it were possible from previous 
knowledge of C and K<jp to obtain values of U^ (t) from the experimental 
data as indicated previously, then the problem reduces to finding the 
value of Kg which produces a computed curve for Up(t) that best fits those 
calculated values.
It is easier, however, to solve for Ug and fit the combined 
expression Ug + Up to the observed uptakes. From Equation 4
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Ug(t) - ^Kg Ug(t)dt + constant (8)
Whilst a general expression for Ug(t), based on the boundary condition 
Ug(t) = Ug(T) at time T, could be developed, it is more convenient in 
practice to make certain simplifications. The tracer concentration in 
plasma. Ip, can be expressed as a sum of exponential terms thus enabling
the integration in the expression for Up(Equation 7) to be performed.
It is then possible to obtain an analytical expression for Ug, and hence.
Up + Ug (as will be described later in Section 1.9). Solutions for C,
K^p, Up(T) and Ug(T) may be found by fitting the computed U^ + Ug
curve to the experimental data.
The preceding discussion serves as an introduction to the following 
review of published work on compartmental analysis of ion uptake by the 
human thyroid gland. In some publications very few details are given and 
the present description of the analyses is necessarily brief.
1.6 Comnartmental Analysis of Iodide fata - Berson & Yalow (12)
Methods and results. Berson and Yalow studied the uptake of ^^^I — 
iodide in untreated subjects (binding studies) and in subjects wiio had been 
given antithyroid drugs to block organification of iodine (trapping 
studies). In one group of thyrotoxic subjects, binding and trapping 
studies were carried out on the same day. Investigations consisted of 
serial determinations of thyroid uptake (using an uptake counter) for 
at least 30 minutes following intravenous administration of the tracer,. 
Measurements were also made of plasma radioactivity and of the urinary 
excretion of the tracer. Intravenous sodium thiocyanate was used to 
check for the presence of dischargeable - iodide.
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The variation of uptake with time in the trapping study always had 
the same form - thyroidal radioactivity increased with time, reaching a 
peak value between 5 and 120 minutes, and then declined in equilibrium 
with plasma radioactivity* For analysis, thyroid uptake and plasma 
observations at any time were expressed in terms of the dose retained in 
the body (which was determined from the urinary excretion measurements). 
Let these be Upland Ip*respectively. Beginning with an equation 
identical to Equation 1, except that the clearance, C, is replaced by 
Kp^V (where Kp,p is the rate constant of transfer between plasma and 
thyroid, and 7 is the plasma volume) Berson and Yalow showed that, at any 
time,
%  = (dUp'/clt)/(Ip'S - U >)
and
KppS = KpT 7
S, with the dimension of volume, is the thyroidal iodide s^mce at 
equilibrium (i.e. when thyroid uptake falls in parallel with plasma radio­
activity) so that
S = Up* (equilibrium)
Ip * (equilibrium)
Inherent in this derivation is the assumption (which was justified by the 
authors) that the rate constant of loss of tracer from the body is very small 
compared to K p^ and so could be neglected.
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These expressions were used to evaluate the unknown parameters 
Kpp and Kp^ V^, the gradient dUg'/dt at any given time (typically at 4-9 
minutes) being obtained by drawing the tangent to the curve of versus 
time. The mean (1 sd) exit rate in 21 thyrotoxic subjects was O.O3B - 
0.024 minute while in 1 normal subject the exit rate was 0.047 minute 
Corresponding values for Kp^ pV (equivalent to unidirectional clearance in 
the "open" compartment model) were 336.6 4 2$6.7 and 40.0 ml minute”"^ 
respectively.
In the binding studies an attempt was made to determine the binding 
rate by the graphical method outlined earlier (Section 1.5)* This 
required that and Kp^V (=C) be determined in a separate trapping study. 
Once these are known, the amount of trapped tracer can in theory be 
obtained using a modified version of Equation 5, Thus
Up = (KpT V Ip - d (Up + Ug)/dt)/Kpp
where d(Up + Ug)/dt may be obtained from the observed thyroid uptake curve. 
Estimates uf Ug, may be obtained by subtracting these calculated values of 
Up from the observed uptakes. The binding rate follows from Equation 4,
Kg = (dUg/at)^^
When the results from 6 previously untreated thyrotoxic subjects were 
subjected to this form of analysis, it was found impossible to construct 
a curve for Up, the unbound uptake. (The calculated values were scattered 
about zero within the limits of experimental error). These observations 
suggested that binding must have occurred almost instantaneously and the 
authors estimated a lower limit of 0.5—1 .0 minute”"^ for the binding rate.
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Further corroboration for this was obtained by testing for the presence of
dischargeable radioiodide in an group of 17 thyrotoxic and normal subjects.
Sodium thoicyanate (ig) vas given intravenously at times varying from
9-50 minutes after the tracer. In l6 cases there vas no detectable
discharge of radioactivity from the thyroid and only a small, if at all,
discharge in the remaining subject.
Another feature of the binding studies vas that the net clearance
vas virtually constant from 4 minutes onwards (see Section 1,4) and was
equal in magnitude to the unidirectional clearance. This suggested that
essentially all the trapped iodide was bound, in other words, that the
binding rate was much greater than the exit rate. Successful analysis
was, however, reported in one case-a patient treated with ^^^I - iodide
for thyrotoxicosis 5 months previously. Satisfactory curves for free
and bound tracer were obtained, thus allowing calculation of the binding
rate. The estimated values for clearance, exit rate and binding rate
were 143.0 ml minute 0.050 minute and 0.112 minute respectively.
Discussion. The methods of Berson and Yalow suffer the
disadvantage that separate trapping studies require to be performed in
the estimation of binding rate. Furthermore, their method of measuring
thyroid uptake is liable to error because of the problem of estimating
extra-thyroidal activity (see Chapter 4). The authors themselves
expressed reservations also about the implied assumption that there was
no release of organified tracer during the period of investigation.
They pointed out that, in patients with extremely active glands detectable
131
amounts of protein bound I had been found at times as early as 20 
minutes following administration of the tracer.
A further deficiency is the graphical approach to the analysis.
It does not provide a measure of "goodness of fit" to the experimental
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data (27). There is also the problem of errors due to difficulties 
in the graphical estimation of gradients.
1.7 Compartmental Analysis of Iodide Data - Ingbar (.31)
Methods and Results, The experimental data collected by Ingbar 
consisted of serial measurements of thyroid uptake (using an uptake
131
counter) from 1-3 hours following intravenous administration of I- 
iodide. Plasma radioactivity was measured over the same period, 
during which time it was found to decrease in a single exponential 
manner. Both normal and thyrotoxic subjects were investigated. The 
methods employed did not require prior administration of antithyroid 
drugs.
Analysis of the data was approached from a different standpoint 
from that in the introductory discussion on compartmental analysis 
(Section 1.5). Ingbar assumed that there is immediate mixing of tracer 
between the plasma and intra-thyroidal iodide compartments. This 
results in an instantaneous uptake of free radioiodide which 
subsequently diminishes in parallel with the plasma radioactivity.
(Some experimental justification for this concept was given by noting 
that measurable uptakes had been found at times less than 1-2 minutes.
In one example, the uptake was 19% of the dose in less than 2 
minutes). If it is further assumed that there is no release of 
organified tracer during the period of investigation, and that plasma 
radioactivity falls monoexponentially, an expression for the binding 
rate of intra-thyroidal iodide (Kg) can be derived. This is based 
on the selection of two points from each of the thyroid uptake and 
plasma radioactivity curves. Let these be and U2, Ip^  and Ip^ ,
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respectively, at the same two times in each curve. If K is the rate 
constant of the plasma curve and 1^^ the intercept at time zero, then
where U^, theoretically the maximum possible uptake by the thyroid 
(assuming no release of organified tracer at any time), is given by
U_ = (I U - I TJ )/(I - I )
M PI 2 P2 1 PI P2
and S  , the thyroidal iodide space, is given by
Data from 28 normal and 20 untreated thyrotoxic subjects were 
analysed by this method. Mean binding rates (tsd) in the two groups 
were estimated -to be 0,015^0.003 minute"^ and 0.065-0.040 minute"’^ 
respectively. (Various other parameters were evaluated by Ingbar 
but these cannot be related, readily, to the parameters of the "open" 
compartmental models and are therefore excluded from this present 
review). These estimates of binding rate are at least one-order 
of magnitude less than those of Berson and Yalow (Section 1,6) and 
suggest that binding is not instantaneous,- It follows that a 
considerable proportion of radioiodide would remain unbound in the 
thyroid for some time. In support of this, Ingbar was able to
demonstrate the presence of dischargeable radioactivity in 5 out of 6 
thyrotoxic subjects who were given 1,5 g sodium thiocyanate, 
Ihtravenously, 30-60 minutes after the tracer. Quantitative details
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were not given except in one case where a discharge of 10-15% of 
the uptake was reported. These results again conflict with the work 
of Berson and Yalow (Section 1.6) who found no evidence of dischargeable 
tracer in most of their patients.
Discussion. The assumptions in Ingbar*s analysis have been 
criticised by Berson and Yalow (12) and by other workers (23, 56). One
of the main defects is the assumption that the injected radioiodide 
exchanges immediately with the intra-thyroidal iodide pool, in other 
words, that equilibrium is reached instantaneously. The author, 
aware of this problem, argued that the resulting errors were likely to 
be relatively small. However this is debatable. For instance, in 
some of Berson & Yalow * s trapping studies (12) equilibrium was not 
reached until 1 hour or so after administration of the tracer.
With regard to the positive discharge results in thyrotoxic 
subjects, it could well be that the tracer released from the thyroid 
was organified, since thiocyanate is known to interfere with the 
binding process (1, 2, 26, 57). The dose of thiocyanate - greater 
than in the studies of Berson and Yalow (Section 1.6) - might have 
been sufficient to cause discharge of organified tracer.
1.8 Compartmental Analysis of Pertechnetate Hi’ta - Shimmins et al (41)
Methods and results. Shimmins et al used a radioisotope scanner 
in their studies of the early uptake of ^ m^^c _ pertechnetate by the 
thyroid gland. This allowed more accurate estimation of extra- 
thyroidal activity (see Chapter 4) and hence the uptake data were 
probably more accurate than in previous studies (Sections 1.6 and 1,7). 
Both normal and thyrotoxic subjects were studied. Scanning commenced
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1 minute after intravenous administration of the tracer and continued 
for a further 40-45 minutes. Each scan took 4 minutes and so the 
first uptake point was at 3 minutes. Plasma radioactivity was measured 
over the period 2-45 minutes.
The variation of thyroidal uptake of ^ ^m^g _ pertechnetate was 
found to be similar to that for radioiodide in Berson and Yalow's 
trapping studies (Section 1.6). Maximum uptake occurred before 40 
minutes and in most cases the uptake curve had begun to decline in 
parallel with plasma radioactivity before the end of the study.
Analysis of the data was based on a "closed" compartment model 
with binding blocked (Section 1.2), but the final results were 
expressed in terms of the parameters of the corresponding "open" 
compartment model. The method was essentially the graphical one 
outlined in the introductory discussion (Section 1.5). Tangents to 
the thyroid uptake curve were drawn at various points (typically at 
3, 10, 20, 30 and 35 minutes) to determine the gradients dU^ /dt.
Plots were then made of (1/Ip)(dUp/dt) versus TJp/Ip, where Ip is the 
plasma concentration at these same times. The plotted values could 
be fitted satisfactorily by a straight line, which confirmed that 
there was virtually no binding of the tracer. Estimates of the 
unidirectional clearance (C) and exit rate (Kpp) were determined from 
the intercept on the appropriate axis and from the slope of the line, 
respectively.
The unidirectional clearance and exit rate (mean±sd) of 
pertechnetate in 9 normal subjects was 36.8^23.7 ml minute and 
0.083^0.048 minute respectively. Corresponding values in 13 .
thyrotoxic subjects were 287.0^226.0 ml minute"^ and 0,088^0.031 
minuté"^ .
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Discussion. Tie one main defect in the work of Shimmins et al 
is the graphical approach to analysis of the data. Graphical estimates 
of gradient are subject to error and there is no measure of "goodness 
of fit" to the experimental data (27). Very much depends on the 
gradients at early times. The points from later times on the straight 
line plot are of little value since these are found to be bunched 
together ' (which is a consequence of final equilibrium between thyroidal 
and plasma tracer concentration).
1.9 Compartmental Analysis of Iodide and Pertechnetate Data -
Robertson et al (27. 39)
Methods and results. Robertson et al (39) reported kinetic
studies of ^^Ij-iodide uptake by the thyroid, whilst Robertson (2?)
Ill 99mreported similar studies of both I-iodide and Tc-pertechnetate.
In each case, measurements of thyroid uptake were made using the same
radioisotope scanning technique described in Section 1,8. Studies
were continued' for up to 150 minutes following Intravenous administration
of the tracer. The disappearance of radioactivity from plasma was
expressed as a sum of two or three exponential terms. Both normal
and thyrotoxic subjects were investigated, in some cases before and
after the administration of antithyroid drugs. Data were analysed
on the basis of the "open" three-compartment binding model (Section
1.5) with the binding rate set to zero when appropriate.
Robertson compared various methods of estimating parameters of 
the model. These consisted of the graphical method used by Shimmins 
et al (Section 1.8), a curve fitting method using an analogue 
computer and a "least sura of squares" curve fitting method using a
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digital computer. It vas noted that the first two have the 
disadvantage of having no inherent estimate of the "goodness of fit" 
to the experimental data. Furthermore the graphical method was liable 
to error owing to difficulties in the determination of gradients, and 
the analogue method was found to be tedious and time consuming. The 
method of choice was that using a digital computer. It provided an 
objective assessment of "goodness of fit" and it was faster than the 
other methods.
Only the digital method, which follows on from the introductory 
discussion (Section 1.5), will be considered here. The method of 
analysis for ^^^Tc-pertechnetate data and for ^^^I-iodide data, when 
binding was completely inhibited, is described first. Equation 2, 
which gives the free uptake at any time in the absence of binding, 
is re-written as
Uj,(t) = C f.(t) + g(t) (9)
where
f(t) = I e
® J t p
dt
and
(t) - Up(T)e "'^P
with Ip, the plasma radioactivity, expressed as a sum of three 
exponential terms, i.e.
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Ip(t) = Ÿ  '
the expression for f(t) is integrated directly to yield 
f(t) = ^  -e
i=l
The free uptake at any time is thereby expressed as a function of the 
variables G, K^ p, TJp(T) and T.
An iterative programme was written which searched for those 
parameter values that produced the least sum of differences squared 
between the observed uptake data and the computed values.
Restrictions were placed, however, on the variables Up(T) and T because 
the computed curve was constrained to pass through the first observed 
uptake point. In other words, these two parameters were made equal 
to the first observed uptake, and the time of that uptake, respectively. 
The task was simplified further by the use of an analytical 
approximation for the optimum value of 0 for each value of chosen 
in the search procedure. Firstly, an estimate of C for each observed 
point, j, was obtained by re-arrangement of Equation 9, thus
The optimum value for C was then taken to be the mean value of Cj over 
all data points,
A similar approach was used in the treatment of 131l-iodlde 
data from the binding gland, but the analysis is complicated by the
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addition of the extra parameter Kg, The thyroid uptake, U(t) at any
given time includes an unbound component Up(t) and a bound component
Ug(t) (Equations 7 and 8). With the additional boundary condition
U (t) = U (T) at time T and with plasma radioactivity expressed again 
B B
as a sura of three exponential terms, the following equations were 
derived;
ïï^ (t) = C y  Aie-%^ -Aie
F
(K^p+Kg- Kp)
^ Up\i/e(T)  "
and
U p U ) = C K B y  A.e-^1^ _ Aie-^t
u K (^e"(^ TF'*^ %)'^  "(K^ p-KKg)T^  ^  j^ e^(KTP’^KB-Ki) T
^  (Kjp+ Kg- K^ )
+ Ptt(T)Kb (1 -0 "(%•» %)(t-T)^ + y (T)
For convenience the total thyroid uptake was expressed in terms of C 
and two functions that are independent of C, thus
U(t) = Dj,(t) + Ug(t) = C F(t) + Q(t) (10)
where
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and
F(t) = Aie-Klf " (%P^%)(t-T))
+ _e -(KTp^Kg)T^  ^  A^e^^TF-KB-U)^
(Ktp+Kb) 6 l  ( % - ^ V h ^
Q(t) = TJp(t) e -( V % )
(Kjp+Kg)
+ Ug(T)
In the curve fitting procedure the computed uptake curve vas 
again constrained to pass through the first observed uptake point.
The boundary value U^(T)vas taken to be 90% of that uptake and Ug(T) 
vas taken to be 10%, Tliis assumed that 10% of the first uptake 
measurement (at 2-3 minutes after administration of the tracer) is 
organically bound. The procedure was further simplified, as before, 
by an approximation for the optimum value of C for each value of Kpp
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and Kg in successive iterations. Firstly, an estimate of C for each 
observed point, j, was obtained by re-arrangement of Equation 10, thus
The optimum value for C was then taken to be the mean value of Gj over 
all data points. Ttius the problem was reduced to finding, by 
iterative techniques, those values of K^p and Kg that produced a "least 
sum of squares" fit to the observed uptake data,
Pertechnetate studies were performed in 36 thyrotoxic and 37 
normal subjects. The mean values ( s^d)for unidirectional clearance 
and exit rate in the toxic group were 138,0^144,0 ml minute”  ^and 
0,073-0,042 minute"^ respectively. Corresponding values in the 
normal group were 19,7^12-,6 ml minute"^ and 0.075-0.036 minute"^ ^
These results are similar in magnitude to those of Shimmins et al 
(Section 1,8).
The kinetics of pertechnetate uptake before and after the 
administration of carbimazole (120 mg over 24 hours) where studied in 
7 thyrotoxic and 11 normal subjects. Both unidirectional clearance 
and exit rate in the thyrotoxic group were found to be significantly 
increased by the drug,'but no changes were detected in the normal group,
Tlie uptake of ^^^I-iodide after the same dosage of carbimazole 
was studied in 6 thyrotoxic and 9 normal subjects. Mean values 
(isd) of 250,0-165,0 ml minute"*^  and 0,036 0^ ,020 minute"^ were 
found in the thyrotoxic group for unidirectional clearance and exit 
rate respectively. Corresponding values in the normal group were 
40.2-29 ,4 ml minute"^ and 0,037^0.033 minute'"^ . These results, when
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compared with those for pertechnetate, suggest that, while the 
unidirectional clearance of iodide may be greater, the exit rate is 
less,. The results for iodide agree with those found by Berson and. 
Yalow in their trapping studies (Section 1-6),
131
Binding studies with I-iodide were performed in 15 untreated 
thyrotoxic and 7 normal subjects, Kean values (-sd) for unidirectional 
clearance in the two groups were 196,0^160,0 and 36.8 9^,5 ml minute"*^  
respectively. The mean (tsd) exit rates were 0,02240,011 and 
0,03o4o,016 minute and binding rates, 0,11010,043 a.nd 0,066i0.040 
minute""^  respectively. Both unidirectional clearance and binding 
rate were significantly greater in the thyrotoxic group,
Tliese binding rate results for iodide are similar in magnitude 
to those reported by Ingbar (Section 1,7) but considerably less than 
those reported by Berson & Yalow (Section 1.6). Some evidence that 
the values might be underestimates of the actual binding rate was 
found in the results of early potassium perchlorate discharge studies,. 
No discharge was found in any of 11 untreated thyrotoxic and 6 normal 
subjects, who were given an oral dose of 500 mg potassium perchlorate 
20 minutes after the tracer. However, if predictions based on the 
Computed binding rates had been correct a few patients should have 
manifested significant discharge.
Discussion. The work of Robertson et al, while a major advance 
in the digital analysis of thyroid uptake data, is not without defects. 
One weakness is the choice of the first uptake point as a boundary 
condition. This constrains the computed curve to pass through that 
point. Further constraints are placed on the analysis, in the case 
of the binding gland, by the assumption that 10% of the first uptake 
is organically bound. It was argued that this assumption was justified
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by the ensuing estimates for binding rate. Some limited 
investigation of the problem revealed that alteration of the bound 
fraction by a factor of three had little effect upon the parameter 
estimates. However, reported values of binding rate for iodide 
vary by as much as a factor of 67 (Section 1,12) and the constraint 
imposed upon the optimisation procedure would seem too restrictive.
One final point is that no errors were given for the parameter 
estimates. Unlike the previous graphical analyses (Sections 1.6-1,8), 
the method of "least sum of squares" does allow calculation of random 
errors due to variation in experimental data (58), However this 
facility was not exploited by Robertson et al,
1,10 Compartmental Analysis of Iodide and Pertechnetate Data -
Gray ■■(.281
Methods and results. Gray used a specially collimated uptake 
counter (59) that minimised the contribution from extra-thyroidal 
activity in his studies of thyroidal uptake. Both ^^^I-iodide and 
99m^2_pgrtechnetate were studied. The tracers were given together 
intravenously and neck radioactivity recorded continuously for a 
period of 20 minutes. Measurements were also made of venous plasma 
radioactivity. At the end of the uptake period sodium perchlorate 
was given intravenously and sufficient time was given for any discharge 
of thyroid radioactivity to occur, A second dose of and '^^Tc
was then given which allowed an estimate of extra-thyroidal activity 
to be made. Normal controls, untreated thyrotoxic subjects, and 
thyrotoxic subjects on carbimazole therapy, were investigated.
Before analysis a correction was made to the venous radioactivity 
curve to approximate the variation of tracer concentration in arterial 
plasma. This was introduced because of a previous observation (53)
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that radioiodide levels were greater in arterial plasma at early 
times. The correction factors were based on further observations of 
arterio/venous differences in the first few minutes after the 
administration of and "^^ T^c (see Section 3.2), Application of
these factors resulted in the modified plasma curves for the latter 
having a starting value at zero time of 0,03% dose ml and for 
a starting value of 0,02% dose ml”!. By 6 minutes after 
administration of the tracer, the simulated arterial curve was 
virtually identical to the original venous curve.
The analysis procedure, when binding was absent, was essentially 
the graphical approach of Shimmins et al (Section 1,8), All ^^^Tc 
data and data from drug-treated thyrotoxic subjects were
analysed in this manner. In some cases the data were also subjected
to analogue computation. However, owing to difficulties in precise
curve fitting with the analogue computer, correlation between the two 
methods was disappointing.
A simple approach - the estimation of net clearance - was used 
in the treatment of ^^^I-iodide data from the normally binding gland. 
This was based on two pieces of evidence. Firstly, thyroid clearance 
was noted to be constant when arterial radioactivity levels, rather 
than the observed venous values, were used (Section 1,4). In other 
Words, there is no return of free tracer to blood, the binding rate 
being much greater than the exit rate. The observed net clearance 
was therefore considered to be a good estimate of the unidirectional 
clearance. Secondly, no dischargeable radioactivity was found in 29 
normal and 12 untreated thyrotoxic subjects who were given intravenous 
sodium perchlorate (200 mg) at the early time of 10 minutes after the 
tracer. It was deduced from these discharge results that binding is
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virtually instantaneous and so there would be essentially no free 
radioiodide present in the gland at any time. The net clearance 
would, therefore, be constant and equal to the unidirectional 
clearance.
In such circumstances it is virtually impossible to obtain 
accurate estimates of the binding and exit rates (see Section 2.5). 
Hov/ever, Gray gave an approximate value of 1.0 minute"*^  for the 
binding rate of iodide in normal and thyrotoxic glands. Estimates 
of exit late were obtained from the trapping studies.
Gray also performed kinetic studies in subjects with binding 
defects such as occur in Hashimoto'g thyroiditis, Pendred's syndrome 
and after radioiodide therapy. The object was to estimate the 
binding rate of iodide. This was achieved by an empirical method 
which was based on the equations of the open three-compartment binding 
model (Section 1.5), and which made use of the analogue computer.
By generating a large series of uptake curves for different parameter 
values. Gray was able to show that binding rate was related to the 
fraction of uptake discharged by perchlorate at 10 minutes. The 
relationship was found to be virtually independent of unidirectional 
clearance and exit rate. Essential to these derivations, however, 
was the assumption that perchlorate reduces the binding rate to 
negligible levels in patients with defective organification, (The 
assumption was based on comparative observations of the exit rate of 
^^^I-iodide and ^^^Tc-pertechnetate before and after perchlorate.
It was predicted that, if binding still continued after perchlorate, 
there would be a relative increase in the exit rate of iodide 
(Section 2,6), However, no such increase was observed).
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The kinetics of ^^^I-iodide and ^9™Tc-pertechnetate were 
studied in 7 normal and 13 untreated thyrotoxic subjects. A linear 
correlation was found between the unidirectional clearances of iodide 
and pertechnetate, the former being approximately 2-3 times greater.
The mean (-sd) unidirectional clearance for iodide was 28.0*13.0 and 
222,0-138.0 ml minute”  ^in the normal and thyrotoxic group respectively, 
Corresponding values for pertechnetate were 19.0-8.0 and 93.0*53.0 ml 
minute""* respectively. Mean exit rates for pertechnetate were 
0.069*0.021 and 0,081*0.027 minute”* in the normal and thyrotoxic 
group respectively. These results are similar to those in previous 
studies (Sections 1.6, 1.8, 1.9).
Comparative studies of the two anions were also made in 14 
thyrotoxic subjects on carbimazole therapy. Again the unidirectional 
clearance of iodide was 2-3 times greater than that for pertechnetate. 
Mean values (*sd) were 167.6*57.7 for iodide and 76,8*24.2 ml minute”* 
for pertechnetate. There was good correlation between the exit rates 
for the two ions, the mean value being 0.062*0,024 for iodide and 
0.088*0.038 minute”* for pertechnetate.
As indicated earlier, the binding rate for iodide in normal and 
untreated thyrotoxic subjects was estimated to be approximately 1.0 
minute”*. The estimated values in patients with binding defects 
were considerably less. In 15 patients with Hashimoto’s disease, 
the mean (*sd) binding rate was 0.2X6*0.096 minute*"*; in 3 patients 
with Pendred's syidrome, the mean was 0,230*0.120 minute”*; in 5 
thyrotoxic subjects who had received radioiodide therapy, the mean 
was 0,210*0.070 minute"!.
—  —
Discussion. The use of simulated arterial, rather than 
observed venous levels of tracer, in Gray’s work was a significant 
advance in the analysis of kinetic uptake data. With this innovation, 
the clearance of radioiodide, in the nomally binding gland, was found 
to be constant from early times and thus it was deduced that binding 
rate is much greater than exit rate. The absence of dischargeable 
iodide at the early time of 10 minutes after the tracer was a further 
indication that the binding rate is relatively high. These findings 
lend support to the earlier conclusions of Berson and Yalow (Section
1.6) with regard to binding rate in the uninhibited gland.
One aspect of the work that could be criticised is the postulate 
that perchlorate completely inhibits organification in subjects with 
defects in that function of the gland (Section 3.8). It will be 
shown later (Section 6.3) that this can lead to the binding rate being 
considerably over-estimated. Gray referred to animal studies (57) 
that, possibly, gave support to his postulate. However the perchlorate 
levels required in those studies to produce binding inhibition were 
exceedingly high (Section 3.8).
Another criticism is that fact no rigorous estimates were made 
of errors in the final results due to variations in the experimental 
data. Errors were given for the results of the trapping studies but 
these referred only to uncertainty in fitting the final straight line 
in the graphical analysis (Section 1.8), No consideration was given, 
for example, to the problem of determining gradients from the observed 
uptake data.
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1,11 Coïïipartmentai Analysis of Iodide and Pertechnetate Data -
Various Authors
Larsson (23) used the method developed by Ingbar (Section 1*7) 
to determine binding rates for iodide before and after the 
administration of the antithyroid drug, thiouracil. Mean values (*sd)in 
4 untreated thyrotoxic and 5 normal subjects were 0,097*0,056 and 
0,027*0.014 minute”* respectively. The effect of thiouracil was to 
reduce the binding rate to a mean value of 0.013*0,003 minute”! in 5 
thyrotoxic subjects under treatment with the drug. In one normal 
subject given thiouracil (150 mg) the binding rate was estimated to be
0,003 minute”*.
Berson (20) and Rail et al (17) gave values of 0.300-0.330 
minute”* for the exit rate of iodide and a value of 1.0 minute”* for 
the binding rate. Complete details were not given as to how the 
values were derived. These were merely used for illustrative purposes 
in a theoretical consideration of the analysis of iodide kinetic data.
Comparative studies of iodide and pertechnetate kinetics were 
undertaken by Dige - Peterson (49) who used an uptake counter and 
continuous recording facility. The studies covered the first 30 
minutes after intravenous administration of *^^I-iodide and 
pertechnetate. Frequent venous blood samples were taken from 1 minute 
onwards. A graphical analysis, similar to that applied to pertechnetate 
data by Shimmins et al (Section 1,8), was applied to both iodide and 
pertechnetate data when there was no inhibition of binding.
(Justification for neglecting the binding of iodide was based on the 
deduction of Robertson et al (Section 1.9) that the bound component was 
only 10% of the total uptake in the first few minutes). Only the first 
8 minutes of the radioiodide uptake curves were, in fact, included in 
the analysis.
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In 3 untreated thyi'otoxic subjects the mean (*sd) unidirectional 
clearances for iodide and pertechnetate were 679.0*256,0 and 
373.0*19 .7 ml minute”* respectively. The mean exit rate for iodide 
was 0,049*0.041 minute”* and for pertechnetate 0.126*0,058 minute” .^
As in previous studies (Sections 1.9 and I.IO), these results suggest 
that whilst the unidirectional clearance for pertechnetate may be less, 
the exit rate appears to be greater than that for iodide.
The uptake of !31l-iodide and ^^™Tc-pertechnetate was studied 
by Brooke et al (50) using a gamma camera and computer. Uptake data 
were collected over successive 1 minute intervals throughout the 
first 60 minutes after intravenous administration of the tracers.
The form of the plasma radioactivity curve was determined from the 
tracer level in the cardiac regions, the curve being normalised using 
the measured radioactivity in one or two blood samples. (Gray (28) 
has shown that the variation of radioactivity in the cardiac regions 
lies somewhat between that in arterial and that in venous blood)•
Initially the analysis consisted of estimation of early and 
late clearance of the tracers (51). In the case of iodide, this 
approach permitted the level of binding inhibition, produced by 
varying doses of antithyroid drug, to be quantified as follows;-
Binding inhibition (%) = 100 (l - Gg/C)
where C is the earliest measured clearance (taken to represent
unidirectional clearance), and Cg is the equilibrium clearance, 
measured at that point in the uptake curve when clearance became
constant. It was found that an oral dose of 0.2 mg methimazole,
given 30 minutes before the tracer, caused 40% inhibition of binding;
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doses greater than 10 mg caused 95% inhibition. Vhen there vas no 
inhibition of binding, there vas no change of iodide clearance with 
time.
Latterly, a "least sum of squares" analysis of the data vas 
carried out using the generalised model building programme (SAAM 
programme) developed by Berman et al (60-62). No details were given 
of the initial conditions and constraints imposed on the parameters, 
but the programme is certainly comprehensive enough to cope with any 
such requirements. The normal range for the unidirectional clearance 
of both iodide and pertechnetate vas reported as 9.5-52.0 ml minute *, 
For the exit rate the range vas 0,028-0,100 minute”*; for the binding 
rate of iodide, a single value of 0.080 minute"* vas given. The 
antithyroid drug, methimazole, given intravenously 30 minutes before 
radioiodide, vas found to markedly reduce the binding rate. A dose 
of 1 mg reduced the binding rate to 0.020 minute”*, while a dose of 
2mg reduced it to 0,008 minute"*. There was no measurable binding 
of iodide with a dose of 40 mg methimazole.
These values reported by Brooke et al (50) for the unidirectional 
clearance and exit rate of the two anions are similar to the results 
discussed previously (Sections 1.6, 1.8-1,10), However the value 
given for the binding rate of iodide in the uninhibited gland lies at 
the lower end of the reported range (Section 1.12). Such a value, 
similar in magnitude to the estimated exit rate, is difficult to 
reconcile with the authors’ observation of a constant iodide clearance 
under normal binding conditions. Before that can happen, the binding 
rate requires to be much greater than the exit rate (Section 2.5), .
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1.12 Discussion of Published Coinpartmental Analyses
All the results mentioned in Sections 1.6-1.11 are compared in 
Table 1. In normal subjects, reported values for the mean 
unidirectional clearance range from 28,0-36.8 ml minute”* for iodide 
and 19,0-36,8 ml minute”* for pertechnetate; in thyrotoxic subjects 
the ranges are 196,0-679,0 ml minute”* for iodide and 93.0-373.0 ml 
minute"* for pertechnetate. Exit rate is similar in both normal and 
thyrotoxic subjects, reported mean values ranging from 0.022-0.062 
minute”  ^for iodide and 0,069-0,126 minute”* for pertechnetate. 
Overall, the results suggest that whilst the unidirectional clearance 
of pertechnetate is less than that of iodide, the exit rate may be 
greater.
In the case of iodide, there would appear to be reasonable 
agreement amongst the various studies as far as unidirectional 
clearance and exit rate are concerned. However, estimates of binding 
rate in the uninhibited gland vary by as much as a factor of 67 (i.e. 
from 0.015-1.0 minute”*). Such differences seem unlikely to be due 
to biological variation.
Evidence that the problem might be technical in origin can 
be gleaned from the work of Gray et al (Section I.IO). These authors 
were the first to apply arterial blood levels of radioiodide, which 
would seem to be appropriate, in the calculation of clearance. As 
a consequence,clearance was found to be constant at all times, i.e. 
binding rate is very much greater than exit rate. In such 
circumstances it is difficult to quantify binding rate (Section 2.5). 
If venous blood levels are used, however, net clearance does vary with 
time (Section 1.4), which might explain those reported binding rates 
which are comparable in magnitude to the exit rate.
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Further support for .a relatively high binding rate lies in the 
absence of dischargeable radioiodide reported by Berson and Yalow 
(Section 1.6), by Robertson (Section 1.9) and by Gray (Section I.IO), 
The results, especially from the studies by Gray in which perchlorate 
was given 10 minutes after the tracer, were considered not to be 
consistent with the lower estimates of binding rate in Table 1.
There is a fair degree of uniformity amongst the various studies 
as far as the results for pertechnetate are concerned. There would 
appear to be no significant binding of the anion on the basis of 
graphical analysis (Section 1.8), Whether the small degree of 
pertechnetate binding, known to occur from other work (3-7), can be 
quantified by more sensitive compartmental analysis, is a question 
that remains to be answered.
None of the studies to date has included a rigorous investigation 
of the accuracy of the final results. One likely source of error is 
random variation in the observed data. Secondly, errors may arise if 
the observation period is not carefully selected. It seems unlikely, 
at this stage, that observation periods ranging from 8-150 minutes 
(Sections 1,6, 1.8-1.11) produce results of the same accuracy.
Thirdly, curve fitting techniques can be particularly sensitive to 
inital conditions and constraints on the parameters (63-65).
The present work sets out to apply the open three-compartment 
binding model (Figure 1.2) to the analysis of thyroidal uptake data. 
Every effort will be made to minimise constraint on the parameters of 
the model. Random and systematic error will be evaluated. Arterial 
levels of tracer will be applied, rather than venous levels, in the 
hope that improved numerical analysis will confirm the existence of a 
binding rate for iodide that greatly exceeds exit rate.
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CHAPTER TWO
A NEW METHOD OF ANALYSIS USING THE OPEN THREE-GOMPART^ENT 
BINDING MODEL AND DIGITAL COMPUTING TEGHI4IQUES
2,1 Introduction
Although the thyroid gland may contain at least two iodide pools 
(l), the studies reviewed in Chapter 1 provide some validation for use 
of.those models (Figure 1,1) in kinetic analysis which have a single 
intra-thyroidal iodide compartment (2), Thus the conventional 
approach of choosing the simplest model to simulate the system under 
Investigation (63) was adopted in the present work. No attempt was 
made to apply more complex thyroid models with two or more iodide 
c ompartm ent s,
Since there is now sufficient evidence to show that some 
organification'of pertechnetate occurs (3-7) it seemed appropriate 
to allow for this in any simulation studies.
The model of choice was therefore the open three-compartment 
binding model (Figure 1.2) and this was used throughout in the analysis 
of both iodide and pertechnetate kinetic data. Inherent in the use
of this model is the assumption that any release of organifled 
tracer during the period of investigation is small and may be 
neglected. Experimental evidence in support of this is reviewed in 
Chapter 3.
Having selected a suitable model to describe the trapping arid 
binding functions of the thyroid gland, it is important to determine 
how well the predictions of the model fit experimental observations.
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Various methods have been devised to quantify the degree of fit 
between simulated and experimental data but the method of "least 
sum of squares"' is the one most widely used (58, 64). It has already 
been used in analysis of thyroid kinetic data (Sections 1.9 and 1,11), 
the best fit to experimental data occurring when the sum of squared 
differences between the simulated and experimental data is at a 
minimum,. "Least sum of squares" analysis provides the best estimates 
of the unknown parameters if the differences between simulated and 
experimental data are uncorrelated and are normally distributed about 
zero. The variances of the experimental data also require to be 
equal. A modification is the method of "weighted least sum of squares" 
which is the method of choice when the last condition is not met.
The initial intention in the present work was to make use of the method 
of "weighted least sum of squares" which is applicable in a wider 
variety of situations. It was expected that weighting factors could 
be estimated, when necessary, from the experimental data.
In practice, the optimisation procedure consists of searching 
for minima in the sum of squares function which can be thought of as a 
surface in the parameter space of the model. Bevington (58) has 
produced a useful review of several search procedures which make use 
of digital computing techniques. His guidelines were followed 
closely in this thesis.
An alternative would have been to use the generalised model 
building programme developed by Berman et al (60-62) or a "least sum 
of squares" fitting programme such as produced by the Nottingham 
Algorithms Group (66). However, it was possible to reduce the 
present problem by analytical methods to a simplified calculation.
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A less sophisticated programme, specifically for analysis of thyroid 
kinetic data, was therefore written.
It is necessary when assessing the performance of any model to 
determine the effect of variation in the experimental data on the 
precision of the computed parameters (65). Attention was therefore 
paid to the estimation of errors in the present work. Some attention 
was given also to sensitivity analysis (67-70) which is directed 
towards identifying those parameters that have the greatest effect 
on performance of the system under investigation.
One advantageous feature of the thyroid trapping and binding 
system is that administration of a blocking agent, such as perchlorate, 
allows the quantities of free and bound tracer to be determined at 
any time. This permits certain aspects of the model to be 
independently checked and verified, which is a desirable step in any 
simulation analysis (63). A method of analysing the perchlorate 
discharge phase of a kinetic study \ms, therefore, developed.
Details of the present analysis of thyroidal uptake and discharge 
are given in this chapter. An outline is also given of the computer 
programmes and methods used to determine random errors in the 
parameter estimates.
2,2 Mathematical Derivations for the Uptake Phase
The present analysis follows on from the earlier introduction 
(Section 1,5) and makes use of certain derivations in the work of 
Robertson et al (Section 1,9). They expressed the total uptake of 
tracer in the binding gland, at any time, as
U(t) = CF(t)+G(t)
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where C is the unidirectional clearance and where F(t) and G(t) are 
functions of the exit rate, and Kg, the binding rate. Included
also in the function G(t) are the parameters Up(T) and Ug(T), the 
free and bound uptakes, respectively, at time T.
It is convenient to define T as the time after which the plasma 
tracer level is Icnown precisely, so Uj,(T) and Ug(T) become initial 
values for the free and bound components in the simulated uptake curve. 
These result from the thyroidal clearance of an unknown plasma 
concentration of tracer up to time T. Experimental data points at 
times less than T, cannot be included in the "least sum of squares" 
analysis. Simulation of these is impossible due to lack of 
knowledge about plasma radioactivity. To avoid imposing any 
Constraints in the following analysis,U (T) and U (T) are treated asr D
unknown parameters. The optimisation procedure is designed to yield, 
if possible, realistic values for these variables.
As a first step, the function G(t) is simplified thus,
G(t) = üp(T) H(t) -K Ugd)
where
Thus
U(t) = CF(t) -K Up(T) H(t) + Ub (T)
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Denoting the observed uptakes as with absolute variance Vj,
the weighted sum of squared differences, S, is given by
s = y  (Uo(tj)-ü(tpfAj (11)
summed over all points included in the "least sum of squares" analysis 
(58), The function S depends on the parameters C, Up(T), Ub(T), 
and Kg, Thus minima will occur when
AS/ÙC = ùs/AUp(T) = ^S/^Ug(T) = As/ÜK^p = k/()Kg = 0
(The same set of equations would hold at local maxima of the function 
but these were never observed in practice). Adopting the method of 
kidman and Powsnor (?l) for red-cell survival analysis, the first 
three equations are solved to yield optimum values of the linear 
parameters C, Up(T) and Ub(T) for any Kpp and Kg,. Substituting for 
U(tj) in Equation 11 and equating the partial derivatives to zero,
+ Ug(T)yntj)/Vj
^ j j
= Vuo(tpF(tp/Vj (12)
j
C ^ F ( t p H ( t p A j  ^ V ’ ’) )  H ^(q )/V j ^ UgCT)
jJ
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Thus in any iterative search for the "least sum of squares" only 
the parameters K p^ and Kg need he considered. At each iteration. 
Equations 12-14 can be solved to yield optimum values for the remaining 
parameters.
2 ,3  Location of the Minimum of the Sum of Squares Function
An ICL 1903A digital computer vas used to locate the minimum of 
the sum of squares function and so provide estimates of the various 
parameters. The computer programme vas written in Fortran,
The search procedure is begun by constructing a coarse plot of 
the function S against K ^  and Kg, optimum values for the parameters 
C, Ug(T)' and Ug(T) at each point being determined from Equations 12-14. 
Suitable starting values for the two variables, i.e. values at the 
minimum of the coarse plot, are then chosen and the minimum located 
to any required degree of precision by the gradient search method (58), 
This method was selected because the gradients of the function S were 
determined analytically (Appendix 1) thus avoiding problems due to 
approximations. Furthermore, the method is ideally suited for 
approaching the minimum from distant starting values (58), (The latter 
feature, after some preliminary experience, obviated the need for a 
coarse map in most anlyses).
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Both K(j«p and Kg are incremented simultaneously, with the 
magnitude of the increments adjusted so that the resultant direction of 
travel in the parameter space is along the direction of greatest 
change of S, As in the coarse plot, optimum values for C, Up(T) 
and Ug(T) are calculated for each new set of Krpp and Kg values. 
Following the procedure given by Bevington (58), the appropriate 
increments for each parameter, at any point in the search, are given
V,
lOCpp) = -(()s/0Ktp). DKppZ
l(Kp)= - P s/<)Kr). DKp2
\fT0S/dK^). DRj,p)2 + (pS/àKg). DKg)'
where DK^ and DK^  are chosen at the outset as step sizes for the 
parameters Kpp and Kg.
Instead of calculating the gradients, ÙS/ÙK^^ and Os/ÙK^, after 
each iteration, the search is continued along the original direction 
until the value of S begins to increase. At that point the gradients 
are re-calculated and the search begun in the new direction, Whenever 
the search straddles a minimum, parabolic interpolation of S improves 
the accuracy of locating that minimum. The procedure is terminated 
when the reduction in S, after a change in direction of the search, 
becomes less than 0.1%.
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2,4 Calculation of Random Errors
Bevington (58) has shown how errors in the computed parameters, 
which result from random variations in experimental data, may be 
calculated. His methods were adopted.
The first step is the construction of the curvature matrix which 
is related to the rate of change of gradient of the function S in 
parameter space. Elements of that matrix, R^ ,^ are given by
= (ys/&^ÙAp/2
where the A represent the parameters Kpp> Kg, G, Up(T) and Ug(T), A 
first order approximation, i.e. neglecting the second order partial 
derivatives of the fitting function U(t), is made of these elements* 
iiius,
%  = ^  (<)u ( tp (ùn(tj) /\ ) A j
The error matrix, E, is then obtained by inverting the curvature matrix, 
thus
E = R"*
Errors, DA^ , for each parameter are given by
where the are the diagonal elements of the error matrix.
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In the event of an unweighted analysis being performed 
(Section 2.1), the same procedure is followed but with all Vj=l.
An estimate of the sample variance, V, is obtained from the value of 
S at its minimum. Thus
where the denominator is the number of degrees of freedom in fitting 
N data points with 5 parameters. Errors for each parameter are 
calculated from
(DAp2 = V E ^
where E’ is the error matrix calculated with all Vj=l
Expressions for the first order derivatives of the fitting 
function, U(t), with respect to each parameter are given in Appendix 1,
2,5 Sensitivity Analysis - Some Elementary Observations
There is considerable evidence to suggest that the binding rate 
of iodide, in the uninhibited gland, is much greater than the exit 
rate (Section 1.12), It is of interest, therefore, to determine the 
effect of neglecting K p^, compared to Kp, on the preceding analysis.
When this is done, it can be shown that the function H(t) 
(Section 2,2) equals unity at all times and that F(t) (Section 2.2) 
is a function independent of Kg. Equations 13 and 14 are therefore
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Identical, Only the unidirectional clearance, C, has a unique 
solution, which is independent of K^p and Kp, given by
3_____________ 3 3_________ j_________
3 3 j  1
Any values of Up(T) and U (T) can be shown to be permissible provided,
üj,(T)+ug(T) = y ~  - p y  F(tjA^
r ^ / ^ 3
It can be shown also that the sum of squares function, S 
(■pnnntion ll) , is independent of exit and binding rate when K^»
K^a Thus "least sum of squares" analysis provides a unique value 
for only unidirectional clearance.
With Kp» Krpp, there is no significant loss of unbound tracer 
and.the net clearance at all times is virtually equal to the 
unidirectional clearance. Because of the letter’s independence of 
binding and exit rate, the shape of the uptake curve is dependent only 
upon unidirectional clearance and plasma tracer level. In other words, 
the observed variable, i.e. thyroid uptake, is sensitive only to the 
System parameter C, for the special case where binding rate is much 
greater than exit rate.
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2,6 Simulation of the Perchlorate Discharge Phase
If it is assumed that perchlorate completely blocks further 
thyroidal uptake of tracer (Section 3.8), the rate of change of the 
free and bound components of uptake are given by
düj,/dt = -K'jp Up - K'g Uy (15)
dUg/dt = K'g Up (16)
where and Kp’ are the exit and binding rates, respectively, in the
post-perchlorate phase. If U (T ) and U (T ) are the free and bound
r P B p
components at the time of perchlorate administration. Equations 15-16 
may be solved (28) to yield the future time course of these components. 
Thus,
Uj,(t) = Uj.(T )e"^^'TP'^^'B)’'^
C g (t) = Ug(T ) -  K 'b Uj,(T ) ( i r â l E l i f l l b .
^ P (Ktp' + Kb ')
where t is the time after perchlorate. The total thyroid uptake 
(Up(t) + Up(t)) is given by
U(t) = % ( T p  + K'gUj,(Tp)
(Krp'^ Kg')
Kg' Uy(Tg)^ -(K'g^+K'g)t
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The expression for U(t) may be simplified in terms of a final 
residual uptake, R, and the total uptake, U(Tp) ( (T^ ) ,
at the time perchlorate was given. Thus,
U(t) = R + (U(T
where
R = Ug(Tp) + K'bPf( V  (17)
(k -tp-k >b)
and
K = K'tp +
In practice, values for R and K may be determined by fitting the 
function U(t) to the experimental uptake points, knowledge of U(Tp) 
being assumed. If the study is continued long enough for the 
exponential term to vanish, R is simply determined from the flat tail 
of the uptake curve, A curve stripping approach can then be applied 
to estimate the exponential component. To avoid prolonging discharge 
studies in the present work, a "least sum of squares" analysis was 
developed to estimate the parameters. The approach is basically 
similar to that used in analysis of the uptake phase (Section 2,2).
If with variance V ,^ is the observed uptake at time tj
after perchlorate, then S, the sum of squares function, is given by
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For any given value of K, the optimum value of the linear parameter, R, 
may be found by equating às/^R to zero. Thus substituting for U(tj), 
and differentiating S with repect to R, the optimum" value is given by,
\ —Kt J
Uo(t.)/Vj - U(Tp)2_e j/Vj
In this way the problem is reduced essentially to finding that value 
of K which minimises the sum of squares function,
A simple iterative programme was written which allowed the 
estimation of R and K to be performed on a programmeable calculator 
(Hewlett-Packard Model 9810A), To begin computation, a suitable 
starting value is chosen for K and that value incremented until the 
minimum of S is found. During the search, the optimum value of R is 
computed for each new value of K. Minima are found to any required 
degree of accuracy by reducing the increments of K as the minimum is 
approached. Random errors in the parameter estimates are determined 
from the error matrix just as in analysis of the uptake phase 
(Section 2,4).
Analysis of the discharge phase in this manner serves as a check 
on the results derived from the preceding uptake phase. Successful 
analysis in the latter case will have provided estimates of the free 
and bound uptake at any time. The observed residual, R, is simply 
compared with the value calculated from knowledge of the free and 
bound uptake at the time of perchlorate administration (Equation 17), ' 
This of course requires use of the estimated value of K and knowledge
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of Kg*, the binding rate in the discharge phase.
For reasons which are discussed later (Section 3.8), it may 
be taken that perchlorate, in normal dosage, does not affect binding. 
Thus Kg’ is given the value estimated for binding rate in the uptake 
phase.
2,7 Steady State Equations
It is informative to consider the steady state equations of the 
open three-compartment binding model of the thyroid gland (Figure 1.2), 
At equilibrium, input of iodine to any of the compartments of 
the gland is equal to output. Thus, if SI^ is the stable iodide, 
concentration in plasma and SI,p is the quantity of free iodide in the 
iodide compartment of the gland, then, at equilibrium,
Solving for SI^ yields,
SI^ = C SI^/(K^p+Kg)
The rate of transfer of iodide into the bound compartment is given by,
SIjKg = 0 Sip Y ( K tp^Kb)
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Thus the rate at which stable iodide in plasma is organified 
may be expressed as the product of the plasma iodide concentration, 
Sip, and an effective clearance, C Kg/(K,pp+Kg) • Inspection of the 
latter expression reveals that when the binding rate, K^ , is much 
greater than the exit rate, K p^, the effective clearance is equal to 
the unidirectional clearance, C, The relationship between effective 
clearance, exit rate and binding rate is discussed further in 
Section 5.5.
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CHAPTER THREE
APPLICATION OF THE METHOD - PRACTICAL LIMITATIONS AND SYSTEMATIC ERRORS
3.1 Introduction
A number of factors are considered in this chapter that have a 
bearing on the application of the foregoing method of kinetic analysis 
(Chapter 2). It is important to ascertain whether these impose 
serious limitations on the usefulness of the open three-compartment 
binding model, and to evaluate any systematic errors introduced into 
the final results.
Foremost is the problem of estimating the tracer level in plasma 
perfusing the thyroid. In most previous analyses, tracer levels in 
peripheral venous blood have been taken to represent those in the 
thyroidal blood supply. However, Gray (Section I.IO) used arterial 
plasma levels ühich were considered to be more realistic. In fact 
these were approximated in the routine situation from measurements in 
venous blood. A similar approximation was devised for use in the 
■ present work and the resulting systematic errors investigated.
A particularly difficult period to evaluate in a kinetic study 
is that immediately following intravenous administration of the tracer. 
During this period of mixing, it is virtually impossible to determine 
the levels of tracer presented to the thyroid. The situation is 
further complicated by the fact that iodide and, to a greater extent, 
pertechnetate are bound to plasma protein (l, 72, 73)• Any 
such binding will compete with the thyroidal uptake {process. As a 
consequence the effective unidirectional clearance of tracer is
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likely to diminish as plasma binding reaches saturation level (l). 
Because of these problems,the method of analysis is designed so 
that the early part of an uptake study can be ignored (Section 2.2). 
However, as will be explained, this proved to be an inappropriate 
step to take in the practical situation.
An important assumption in the analysis is that any release of 
organified tracer is small enough to be neglected (Section 2,1),
Some tentative calculations, based on relevant published work, were 
made to determine whether this assumption could be justified. One 
possible way of minimising the effect of any loss of organified tracer 
is to limit the duration of the study. However, this in itself leads 
to difficulties for there has been no previous work to determine the 
time span necessary for satisfactory results. The effect of varying 
the duration of study was therefore investigated.
A practical aspect of the "weighted least sum of squares" 
method is the calculation of suitable weighting factors, which are 
normally taken to be the inverse of the variance (Section 2.2),
However a number of sources may contribute to variance in experimental 
data and it may not always be possible to evaluate the combined effect. 
Thus some effort was made to determine whether there is any need, in 
practice, for weighting factors.
Some consideration has already been given (Section 2.5) to the 
likely effect on the analysis of the binding rate being much greater 
than the exit rate. Under such circumstances, it was shown that only 
the unidirectional clearance would have a unique solution. VThen the 
new method of analysis was applied to radioiodide data from the binding 
gland, there were indeed problems in the computation. These are 
summarised in this chapter.
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Another featüre of the previous chapter is the method proposed 
for checking the analysis, based on the ability of perchlorate to 
discharge free tracer (Section 2,6). However two assumptions were 
made, one being that the administered dose of perchlorate completely 
blocks further uptake and the other being that the perchlorate does 
not affect binding. Some justification for these two assumptions had 
to be found.
3.2 Correction for Arterio/Venous Differences
Methods The present method of approximating arterial tracer 
levels from observations in venous blood is based on the work of Gray 
(28, 74). His studies of normal and thyrotoxic subjects revealed 
that tracer levels for both iodide and pertechnetate were greater in 
arterial blood during the period 0-20 minutes after intravenous 
administration. The mean arterio/venous ratios (±sd) determined at 
various times, in 10 subjects, are given in Table 2; observed ratios 
for iodide and pertechnetate being combined to produce the tabulated 
values.
These results form the basis of the approximation. All 
computation was performed on a progranuneable calculator (Hewlett - 
Packard Model 9S10A), . An outline of the programme follows.
The first step is to fit a curve consisting of two exponential 
components to the observed tracer levels in venous plasma. A curve 
stripping method is used, with the points from 30 minutes onwards being 
used to determine the longer-lived component. Those points in the 
venous curve which relate to the times given in Table 2 are then 
increased by the appropriate arterio/venous ratios. Finally, a curve
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consisting of three exponential components Is fitted to the simulated 
arterial data points. The original venous component from 30 minutes 
onwards is preserved but two new components for the earlier part of 
the curve are found by curve stripping. Simulated arterial curves 
for iodide and pertechnetate are compared with the original venous 
curves in Figure 3*1*
To check the accuracy of the present approximation, the mean 
simulated level in a representative group of subjects was compared with 
the observed arterial levels reported by Gray (28), In 6 subjects
1 on
studied with I-iodide, he found a mean (~sd) arterial concentration 
at 1 minute of 2,0-0.6 x 10"^ % dose ml"^ . The corresponding value in 
10 subjects studied with *^ *^ T^c-pertechnetate was found to be 2,8^0.8 x 
10”  ^% dose ml" .^ In the present study, the mean (±sd) simulated 
concentration in 15 subjects was 2,2-0,5 x 10“  ^% dose ral"^  for iodide 
and 3.0'io,8 x 10”  ^% dose ml  ^for pertechnetate, both at 1 minute after 
intravenous administration of the tracer. The difference between 
these simulated and observed values is not significant (p>0,4).
Systematic errors. Since the original studies of arterio/ 
venous differences (28, 74) revealed considerable variation from subject 
to subject, there is likely to be variable error in using the present 
approximation. It was possible, however, to quantify the error from ■ 
this source by noting the effect on the analysis of changes in magnitude 
of the arterio/venous correction, A number of data sets were analysed 
before and after using extreme values of the observed arterio/venous 
ratios (Table 2) in the arterial approximation programme. The 
resulting mean differences in the estimates of unidirectional clearance, 
exit rate and binding rate are summarised in Table 3. Differences are 
expressed as a percentage of the result with the normal arterio/venous
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Arteria l Curve
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50 PERTECHNETATE
40
30
20
0 20 6040
M inutes A fter Tracer Administration
Application of the arterial approximation 
to the curve derived from observed tracer levels in 
venous plasma.
TABLE 2
OBSERVED ARTERIO/VENOUS RATIOS OF TRACER CONCENTRATION IN PLASMA AT 
VARIOUS TIMES AETï':R INTR4VEN0US ADMINISTRATION OF EITHER 
- IODIDE OR ^9^Tc-“PERTECHNETATE
Time after administration Mean sd) arterio/venous
of tracer (min)
1
2
6
10
20
ratio (10 subjects)
2.13 " 0.65 
1.77 i 0.39 
1.32 t 0.20 
1.23 t 0.17
1.14 - 0.13
TABLE 3
EFFECT ON PARAMETER ESTIMATES OF USING EXTREME ARTERIO/VENOUS RATIOS 
IN THE ARTERIAL APPROXIMATION. DIFFERENCES ARE EXPRESSED 
AS PERCENTAGES OF THE ESTOIATED VALUES WITH THE NORMAL 
ARTERIAL CORRECTION
Difference in 
unidirectional
Difference in 
exit rate (%)
Difference in 
binding rate
clearance ( 5^). ~ ~ m r ^
Upper limits 
of arterio/Venous 
ratios applied
-18 ”3 +35
Louer limits of 
arterio/venous 
ratios applied
4-48 +23 —4^
correction. Results for iodide and pertechnetate have been 
combined.
The results in Table 3 sbou the effect of either overestimating 
or underestimating the true arterial level by the widest possible margin, 
Vhen the true arterial level is badly overestimated, then both 
unidirectional clearance and exit rate will be underestimated, by 
J!S% and 23^ respectively. The binding rate will be overestimated by 
46%, In the case of the true arterial level being badly underestimated 
by the approximation, then both unidirectional clearance and exit rate 
will be overestimated, by 18% and 3% respectively. The binding rate 
will be underestimated by 35%,
These errors are relatively large when compared to the estimated 
random errors (Chapters 5-7) but must be accepted for the practical 
convenience of avoiding arterial sampling. It is unfortunate that 
radioactivity levels in the cardiac area are found not to reflect 
arterial tracer concentration (28), However, many of the investigations 
reported here are studies of the changes in tracer kinetics in 
individiel subjects* so the effect of systematic variations is reduced. 
Furthermore, provided a sufficient number of cases is involved mean 
estimated values for the various parameters in a given thyroid state 
should be reasonably accurate,
3 .3  Initial Conditions
An integral feature of the theoretical analysis (Section 2,2) is 
the facility whereby allowance can be made for uncertainty about plasma 
radioactivity levels Immediatly after the tracer is given. This entails
—  74 —-
setting starting values for the free and bound components of the 
simulated uptake curve, not at time zero, but after a time T. In 
theory, T could be set to 20 minutes which would obviate the need for 
the arterio/venous approximation described in the previous section.
Initial experience soon revealed, however, that, no matter 
the value given to T, realistic values for the initial free and 
bound components of uptake, Up(T) and Ug(T), respectively, would not 
evolve from the analysis. It was apparent that the problem lay not 
in the value given to T, but in giving freedom to both U^ (T) and U^(T), 
Thus some constraint had to be placed on one (or both) of these 
parameters,
Various manoeuvres were investigated but only one was found 
satisfactory. That consisted of constraining Ug(T) to be zero at 
T=0, No restriction is placed on Up(0 )* the initial free uptake.
The least sum ofsquare^'analysis provides an estimate of that parameter.
Implied in this procedure is the hypothesis that phenomena may 
occur immediately at the start of the thyroidal uptake process, which 
cannot be accounted for by the approximated arterial tracer levels.
For example there may well be "instantaneous" uptake due to the 
passing of an initial bolus of tracer through the thyroid. The 
occurrence of very rapid uptake (within the first minute) has already 
been reported (28, 31, 4-6), There may also be a brief period of 
diminishing unidirectional clearance as plasma binding of the tracer 
(Section 3,1) is completed. The net effect would be an apparent 
"instantaneous" uptake, too large to be explained by the final 
unidirectional clearance. Any such "instantaneous" uptake is taken 
to be entirely free, there being no bound component.
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Care has to he taken not to include the point (0,0) in the 
"least sum of squares" analysis. Inclusion of that point would 
contradict the implied hypothesis. Indeed, satisfactory fits to 
observed data were not achieved in the present work when the point 
( 0,0) was included. Similar problems have been encountered in studies 
where an anologue computer was used for the purpose of curve fitting 
(28).
3,4 Release of Organified Tracer
Reservations have been expressed about the validity of 
neglecting the release of organified radioiodine from the thyroid, 
even at early times after administration of the tracer (I6, 23),
Indeed, it has been suggested that there is no practical period 
during which some labelled hormone is not released (16), Experimental 
evidence on the subject has revealed that labelled hormone begins to 
leave the gland within 2 hours in normal subjects (11), and within 1 
hour, even as early as 15 minutes, in thyrotoxic subjects (12, I3), 
However, whether any steps should be taken in practice to allow for 
this, depends on the hormone release rate and concentration of labelled 
hormone in plasma.
There have been a number of studies of the release of organified 
radioiodine from the thyroid, with the results expressed in terms of 
the fractional release rate or biological half-life of iodine in the 
gland (11, 15, 16, 75-77), One problem in experimental determination 
of either parameter is that recycling of the tracer has to be 
prevented by administration of antithyroid drugs, which in themselves
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may increase the release rate from the thyroid (15, 16, 78, 79)*
Thus the values given in the literature for the release rate of 
organified iodine may be overestimates. This means that the following 
argument could well be weighted against the case for neglecting the 
loss of organified tracer.
The most rapid turnover of intra-thyroidal hormone occurs in 
thyrotoxic subjects and, when results are expressed in terms of a 
fractional loss rate, the range of reported values in thyrotoxicosis 
is 8,5 X 10-6 - 1,6 X 10-4 minute"^ (11, 15, 16, 75-77). Thus even 
the maximum reported value is at least 2 orders of magnitude less than 
any of the reported values for the exit rate of iodide (Table 1)• 
Consequently, whenever the bulk of thyroidal uptake is in unbound 
form, loss of organified tracer from the gland will be negligible 
compared to the loss of free tracer.
In the normally binding gland, however, radioiodide is likely 
to be rapidly organified (Section 1,12), leaving a negligible 
proportion in free form. Under these circumstances loss of 
organified tracer may well be the greater. Whether this loss will 
seriously affect thyroidal uptake of tracer, depends on its relation­
ship to the input of tracer. To clarify the issue, a simple 
calculation was performed on kinetic data from an extremely thyrotoxic 
subject, applying the maximum reported value for the fractional loss 
rate of thyroid hormone. The estimated loss of organified tracer 
tracer was only 4*5% of the input rate of tracer at 60 minutes, 
increasing to 27% at 150 minutes.
The matter was further investigated by empirical measurement 
of the organified tracer content of plasma. These studies revealed 
that, even in thyrotoxic subjects, the proportion of organified tracer
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to total tracer concentration in plasma is unlikely to exceed 4% 
at 60 minutes.
Thus theoretical and expirical investigation has revealed that 
for studies of 60 minutes duration, or less, the release of organified 
tracer may be ignored. Any effect of this process on the shape of 
the thyroidal uptake curve, and on plasma radioactivity concentration 
is likely to be negligible. However, for longer studies, the loss of 
organified tracer in extreme cases may have a significant effect during 
the latter part of the study.
3.5 Optimum Time Interval for Data Collection
An empirical approach was employed to determine whether computed 
parameter values are dependent upon the duration of the thyroidal uptake 
study. Use was made of several data sets which were acquired over 
the periods O-6O and 0-150 minutes after intravenous administration 
of the tracer. Analysis was performed in each case using the complete 
data set and again with later data points removed. In this way it 
was possible to compare three different time intervals, namely, 0-30, 
O-6O and 0-150 minutes. Data in the O-I5O minute studies Were too 
sparse to permit comparison of these three time intervals within the 
same data sets*
Results for analysis of pertechnetate data from the intervals 
0-6C> and 0-150 minutes are compared in Table 4. Values are given in 
the table for unidirectional clearance, exit rate, binding rate and 
initial free uptake (Section 3*3)• A similar comparison for iodide 
data from the normally binding gland is presented in Table 5. In this
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case, however, values are given only for unidirectional clearance and 
Initial free uptake (Section 3.7). Results for pertechnetate data 
acquired over the intervals 0—30 and 0—60 minutes are compared in 
Table 6. Similar results for iodide data are compared in Table 7.
Statistical analysis of these results was carried out using 
the Wilcoxon rank test for pair differences (80)• There is no 
significant difference (p>0.l), in the case of either ion, between 
the results for the intervals 0-60 and 0-150 minutes. The same is 
true of all parameters, except the exit rate of pertechnetate (p<0.05), 
for the time intervals 0-30 and 0-60 minutes. Estimates of the 
exit rate of pertechnetate (Table 6) can be seen to be greater, by 
approximately 15% on average, for data acquired over the shorter time 
interval.
These results suggest that a detectable systematic error is 
1 ikely to be introduced only when the study period is restricted to 
30 minutes or less. Studies of 60 minutes duration, and greater, 
are likely to produce virtually identical results. It would appear 
thaty for present purposes, there is no need to extend study of 
thyroidal uptake beyond 60 minutes after the tracer is given.
3.6 ■ Assessment of Weighting Factors
"Weighted least sum of squares" analysis requires each data 
point to be weighted by a factor which is usually taken to be the 
inverse of the absolute variance (Section 2,2). In the present work, 
the data to be analysed consist of estimates of thyroidal uptake which 
are subject to random'error from a number of sources (Chapter 4).
These include factors such as patient movement and variation in
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in physiological activity during the course of the study.
The major source of error, however, is likely to be statistical 
variation in thyroidal and background radioactivity. Unlike other 
sources of error, the variance arising from this source can be 
determined readily (Sections 4*2 and 4*3)* It was decided therefore 
to perform some preliminary analyses before and after applying "count 
rate" variances. The outcome would provide some indication as to 
whether weighting factors would have a significant effect on the 
estimated parameter values#
These exploratory studies revealed that application of "count 
rate" variances had little effect on the results of the "least sum of 
squares" analysis. Two typical examples are presented in Table 8,
The first demonstrates the minimal effect of weighting in a set of 
pertechnetate data, while the second shows a similarly small effect 
in iodide data from a patient with defective binding. Variances 
differed by factors of five and two, respectively, within the two 
sets of data.
Since other sources of error are unlikely to contribute markedly 
to the overall variance, these findings suggest that there is no 
practical necessity for weighting in the present studies.
3*7 Practical Effect of High Binding Rate on Ikta Analysis
In the earlier theoretical discussion (Section 2.5) it was 
shown that if the binding rate is much greater than the exit rate, then 
only the unidirectional clearance and sum of the intial free and bound 
uptake have unique solutions. The latter is modified when, as a 
practical necessity, the initial bound uptake is constrained to have a
TABLE 8
EFFECT OF WEIGHTING ON THE OUTCOME OF LEAST SUM OF SQUARES ANALYSIS
Unidirect­
ional 
clearance 
(ise) _ 
ml min
Exit rate 
(- se) 
min
Binding rate 
(ise) rain
Initial free 
uptake (-se) 
% dose
TcO^-
Unweighted
Weighted
30.6 - 1.1 
29.4 - 1.0
0.153 “ 0,006 
0.147 - 0.005
0.0057 - 0.0004 
0,0056 - 0.0005
0.35 ™ 0.09 
0.44 0.08
I - UnweightedWeighted
84.9 — 4.0
86.9 i 4.1
0.040 - 0,005 
0.043 ” 0.006
0.052 - 0.003 
0.053 - 0.004
1 .0 4 - 0.23  
0.94 - 0 .2 4
value zero (Section 3*3)* 'In these circumstances the initial free
uptake has a unique solution. These consequences of a relatively 
high.binding rate are manifested by the sum of squares function having 
the same minimum value for all exit and binding rates satisfying the 
condition K g »  K,pp.
When the new method of analysis was applied to iodide data from 
the binding gland, computational problems were immediately encountered. 
Full details are given later (Chapter 5). However it suffices to state 
at this stage that the surface near the minimum of the sum of squares, 
in exit/binding rate space, was very flat. In quantitative terms, the 
ratio of the minimum sum of squares, when the exit rate is zero, to that 
at the true minimum was never greater than 3.07 in all cases investigated. 
As a consequence, the estimated parameter values at the true minimum 
had large random errors.
These findings confirm that the binding rate of iodide is 
normally much greater than the exit rate (Section 1.12). Thus only 
unidirectional clearance and initial free uptake may be evaluated. A 
lower limit of 0.150 minute""^  for the binding rate of iodide in the 
uninhibited gland is estimated in Section 5.5.
3.8 Effect of Intravenous Sodium Perchlorate
Intravenous sodium perchlorate was used to block thyroidal 
uptake in the discharge studies undertaken in the present work. This 
meant that the problems of incomplete gastro-intestinal absorption and 
delay in effect (81, 82), associated with the use of oral perchlorate, 
were avoided.
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Various workers have used intravenous sodium perchlorate to 
block uptake of iodide or pertechnetate by the thyroid gland and other 
tissues (28, 56, 81-85). Doses have ranged from 50-450mg, the largest 
dose being that found necessary,in brain scanning, to completely block 
uptake of pertechnetate by the choroid plexus (82).
Blocking of thyroidal uptake. Observations early in the 
present work threw some light on the question of appropriate dosage 
for effective thyroidal blocking. Initially, a dose of 300 mg was 
selected for use in studies to determine the extra-thyroidal neck 
activity seen by an uptake counter (Section 4.2). In the first 
nine subjects, who were all thyrotoxic, neck radioactivity decreased 
continually throughout the observation period in all cases except one. 
This was true for both iodide and pertechnetate. Thus in eight cases, 
300 mg sodium perchlorate effectively blocked thyroidal uptake. In 
the subject who did not demonstrate a falling neck count (who in fact 
had the highest uptake previous to the extra-thyroidal activity study), 
it was estimated that the unidirectional clearance had been reduced by 
a factor of 13 by the perchlorate. The study was repeated giving a 
dose of 600 mg sodium perchlorate, and the usual pattern of falling 
neck activity was observed.
Further information on the efficacy of intravenous perchlorate 
was obtained from discharge studies in four subjects who were given two 
doses of perchlorate. All four subjects were thyrotoxic, two were on 
anti thyroid drug therapy and the remaining two were untreated. The 
first dose of perchlorate (300 mg) was given 60 minutes after the 
simultaneous administration of radioiodide and ^ *^^ Tc-pertechnetate.
A second dose of 600 mg sodium perchlorate was given 30 minutes later. 
Analysis of the discharge phase was performed as described previously 
(Section 2.6).
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As can be seen from Table 9> the residual uptakes after the 
first dose of perchlorate were similar to those after the second dose. 
The observed differences for each anion are not significant (p>0,2) 
on the basis of the Student t test for pair differences (80). Thus 
the first dose of 300 mg seems to have effectively discharged most of 
the available tracer from the gland.
When all these results are considered, it would appear that, 
in most cases, 30Ô rag sodium perchlorate will completely block 
thyroidal uptake. Only in exceptional circumstances will the dose 
require to be increased to 600 mg.
In the present work, the smaller dose (300mg) was used in 
discharge studies. This was considered necessary because many of 
the investigations were repeated at frequent intervals. It seemed 
prudent to restrict the dosage of perchlorate to minimise the possible 
risk of any cumulative effect on gland function. The larger dose 
(600 mg) was useu In all future estimations of extra-thyroidal activity.
Binding rate after perchlorate. Up till recently, it has been 
customary to assume that in such doses perchlorate has little effect 
on the binding function of the thyroid gland (1, 86). (In much 
greater doses perchlorate may well affect binding if extrapolation 
is made from the studies of Greer et al (57) in rats. They found 
that with the lowest dosage tested - 25mg sodium perchlorate to a rat 
weighing 100 g - binding was inhibited by approximately 40%).
Hoveyer Gray (28) made the original postulate that perchlorate in 
normal doses reduces the binding rate to negligible levels in subjects 
with binding defects, but has no significant effect when binding 
is normal.
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Experimental evidence for this vas reputed to have been found 
in comparative measurements of the discharge rate for iodide and 
pertechnetate in the post-perchlorate phase. It can be shown 
theoretically (Section 2.6) that the discharge rate for iodide should 
be greater owing to the presence of a binding rate factor. No such 
relative increase was found and it was concluded that the binding 
rate in the perchlorate discharge phase was negligible.
The present work shows (Chapter 7), however, that typical 
binding rates for iodide in patients with binding defects are small 
compared to the total discharge rate In the perchlorate phase. These would 
not be expected to produce any significant difference in the relative 
discharge rates between iodide and pertechnetate. In this present 
work, therefore, binding rate is assumed not to be affected by 
perchlorate.
3.9 Summary
As a consequence of these considerations and exploratory 
studies, a working procedure was finally adopted which provided a 
reliable and useful means of investigating the early uptake kinetics- 
of iodide and pertechnetate. The essential details are as follows.
(l) For bo^ anions, thyroid uptake data are collected over 
the time interval 0-60 minutes after intravenous 
administration of the tracer. Longer studies would 
require, where appropriate, correction for loss of 
organified tracer (Section 3.4). On the other hand, 
shorter studies could lead to systematic error in the
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parameter estimates (Section 3.5).
(2) Venous blood samples are taken at 2, 10, 20, 30, 40, 50 
and 60 minutes, and estimations made of the tracer 
concentration in plasma, A curve consisting of two 
exponential components is fitted to the plasma data.
This enables an approximate arterial plasma curve, 
consisting of three exponential components, to be constructed 
(Section 3*2)•
(3) The uptake data,with no weighting factors applied 
(Section 3*6), and the approximated arterial data are
analysed by the methods described in Chapter 2. However,
two modifications are made - both the delay time, T,
and the initial bound uptake, Ug(T), are constrained to 
have the value zero (Section 3.3)* The point (0,0) is 
not included in the analysis (Section 3.3).
(4) When analysis of radioiodide data is complete, the minimised 
sum of squares with the exit rate, K^ p, equal to zero is 
compared with the true minimum value. If the ratio is
:^ 3.07, the parameter estimates at the minimum are rejected 
(Section 3.7). The optimum unidirectional clearance and 
initial free uptake with Kpp=0 are accepted instead. In 
these circumstances the analysis indicates that the binding 
rate is much greater than the exit rate.
A lower limit of 0.150 minute"^ is assumed for the
binding rate of iodide in normal and untreated thyrotoxic 
subjects (Section 5.5).
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(6) In discharge studies,sodium perchlorate is given
intravenously in a dose of 300 mg (Section 3.8), 60 minutes 
after the tracer. Observations of thyroidal radioactivity 
are continued thereafter for 30 minutes. Binding is 
is assumed to remain unchanged. The discharge phase is 
analysed as described previously (Section 2.6).
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CHAPTER FOUR
THE MEASUREMENT OF THYROIDAL UPTAKE
4.1 Introduction
A number of factors contribute to errors in the measurement of 
early thyroidal uptake of radioactive iodide or pertechnetate (87-90)• 
These include statistical variations in source count rate and the 
problem of simulating thyroid position and anatomy for calibration 
purposes. One major problem is that of estimating the contribution 
from radioactivity in the blood vessels of the gland, and in other 
tissues, to the output of the detecting device.
In measurements with an uptake counter, different assumptions 
have been made with regard to extra-thyroidal activity (91). For 
example, the uptake over the thigh has been used in the estimation of 
extra-thyroidal activity (31, 42, 92, 93). Alternatively, it has 
been assumed that neck activity, at 2 minutes after injection of the 
tracer, is entirely extra-thyroidal and thereafter varies as blood 
activity (36, 94), or remains a constant fraction of total body 
radioactivity outwith the thyroid and kidneys (95).
The extra-thyroidal activity in the field of view of an uptake 
cpunter has been measured directly, by blocking thyroidal uptake by 
administration of Lugol*s iodine (96), and indirectly, using a 
radioisotope scanner (88, 97, 98). These studies provided a set of 
mean values for routine use as approximations to the extra-thyroidal 
activity in individual subjects. Partial measurement of extra- 
thyroidal activity may be achieved by placing a lead block over the
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thyroid to attenuate radiation arising from the organ (23, 99, lOO)•
Individual precise determination of extra-thyroidal activity is, 
however, important in kinetic studies (37), which has lead to the use 
of improved techniques for measurement of thyroid uptake. One approach, 
using an uptake counter, is to perform two consecutive studies, once 
before and again after blocking thyroidal uptake by the administration 
of perchlorate (49). Inaccuracies in this method can be reduced 
further if the field of view of the counter is restricted by special 
collimation so as to minimise the contribution from extra-thyroidal 
activity (28, 59). A different approach is to use an imaging device 
such as a profile (101-102) or rectilinear scanner (39, 41, 103-105), 
or a gamma camera (7, 40, 43-46, 48, 51, 85, 106-113). ' Areas 
adjacent to the thyroid may be used to estimate the contribution from 
extra-thyroidal activity to counts within the thyroid region.
Two methods of measuring thyroid uptake were used in the present 
work. Firstly, for sequential studies of the kinetic behaviour of 
iodide and pertechnetate in antithyroid drug therapy (Chapter 6) use 
was made of a sodium iodide scintillation counter fitted with an IAEA 
standard collimator (114). No attempt was made to modify the 
collimater since the studies were intended as a follow-up to previously 
reported work with the same counter (115, 116). Both ^^^I-iodide 
(670 KeV) and ^^^^c-pertechnetate (I40 KeV) were studied simultaneously. 
The former radioisotope was used rather than ^ 31l, because the radiation 
dose to the thyroid is lower by a factor of 100 (117), and rather than
123
I (159 KeV), because the photon energy is clearly separated from that 
of Secondly, for studies with only one tracer, for example, the
investigation of iodine binding defects with ^^^I-iodide (Chapter 7),
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use vas made of a gamma camera (Ohlo-Nuclear Series 100) linked to a 
computer (Varian 620/L-lGO)•
Details of these tvo methods and the experimental procedure for 
kinetic studies are given in this chapter.
A.2 The Uptake Counter and Results of Extra-Thyroidal Activity Studies
Method. The counter is placed at 8,5 cm from the neck vith the 
patient in the supine position. Care is taken to exclude the salivary 
glands from the field of view. 50 uCi ^^^I-iodide and 250 uCi^^^ïc- 
pertechnetate in 2,5 ml isotonic saline are injected into the antecubital 
vein and a series of counts are taken, each with a preset time of 
seconds. The first count is taken at 30 seconds, the second at 2 
minutes and succeeding counts at A minute intervals until the end of 
the study. Each study is continued for 60 minutes or, if a subsequent 
perchlorate discharge test is required, a further 30 minutes (Section 
3.9)• Counts are recorded simultaneously in tvo energy intervals, 
120-160 KeV for ‘^'^“Tc, and 400-800 KeV for An aliquot of the
dose solution is placed in a neck phantom (88) and counted under the 
same conditions. A sample of pure is counted likewise to obtain
the contribution from that radioisotope in the energy interval.
The neck counts for each tracer are then expressed in terms of percent 
administered dose, after appropriate correction for radioactive decay.
For determination of the true thyroidal uptake, a separate study 
is performed to estimate the extra-thyroidal contribution to these 
calculated neck uptakes. The same procedure is followed except that 
600 mg sodium perchlorate are given intravenously (Section 3.8) 5 
minutes before the tracers. With thyroidal uptake now completely
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blocked, the resulting neck' count (5^ dose) represents extra-thyroidal 
activity seen by the uptake counter (ETA),
.To calculate thyroidal uptake in the original study without 
perchlorate, allowance has to be made for the fact that the extra- 
thyroidal activity will be less than ETA because of the presence of 
thyroidal uptake. It may be shown that thyroidal uptake dose) is 
related to neck uptake {% dose), in the absence of perchlorate, and 
ETA by
Thyroidal uptake = 100 (Neck uptake - ETA)/( 100 - ETA)
Inherent in this formula is the assumption that any changes in 
tracer kinetics within extra-thyroidal tissues, between the two studies, 
has no further effect upon the parameter ETA, It is well known that 
such changes do occur, since perchlorate inhibits uptake in those 
tissues where iodide and pertechnetate are normally concentrated, such 
as the salivary glands (l). The effect on plasma concentration may 
be variable (84, 118). However, with the salivary glands excluded 
from the direct field of view of the counter, the overall effect of 
these changes in tracer kinetics on ETA were considered to be minimal. 
(Collimator penetration, even for l^^ I, was not a problem.. Vlien a 
thick lead block was placed over the open end of the collimator, the 
observed count was less than 1% dose).
Extra-thyroidal activity. It was considered worthwhile to 
combine all the results from extra-thyroidal activity studies with a 
view to providing an average curve of the variation of ETA with time, 
for each tracer. These would have a longer time span than curves for 
the period 0*30 minutes, previously published for the same uptake
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counter (88, 97) and could be used in any future measurements of 
thyroidal uptake where high precision was not essential.
Extra-thyroidal activity of ^ ^^I-iodide, in 9 thyrotoxic subjects, 
and of ^ ^Tc-pertechnetate, in 8 of the same group of subjects, is 
plotted against time in Figures 4.1 and 4.2 respectively. Second 
order polynomial curves were fitted to these two sets of data by the 
method of "least sum of squares". Thus for ^^^I-iodide,
ETA = 7.92 - 9.15 X lO-^t 9.03 x 10""^  t  ^
and for 99mTc-pertechnetate,
ETA = 8,81 - 9.14 X 10“^t + 9.03 x lo""^  t^
where ETA (% dose) is the mean extra-thyroidal activity at any time, 
t (minutes), in the absence of uptake. The difference between these 
curves reflects the fact that in most cases the extra-thyroidal activity 
for ^ ^^Tc was greater by 0,5-1.0 % dose.
Venous blood samples were taken in 4 of the subjects to compare 
the fall in plasma radioactivity with that in extra-thyroidal activity. 
There was considerable discrepancy between the two curves during the 
first 30 minutes, the fall in plasma radioactivity being the greater. 
From 30 minutes onwards, however, both plasma and extra-thyroidal 
activity fell at approximately the same rate. This fact may be used 
in the calculation of extra-thyroidal activity at times greater than 
60 minutes.
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Figure A.l Extra-thyroidal activity of 132% seen by the uptake 
counter in 9 thyrotoxic subjects given a blocking dose of perchlorate.
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Figure ^ 2  Extra-thyroidal activity of seen by the uptake counter
in 8 thyrotoxic subjects given a blocking dose of perchlorate.
The plasma levels for pertechnetate were consistently greater 
than those for iodide, which may explain the observation that the 
extra-thyroidal for the former was usually greater. That would be 
the case if much of the radioactivity in the field of view of the 
uptake counter were in blood rather than in extra-vascular space.
Counting errors. Unlike random errors arising from other
sources, such as patient movement and physiological variation, those
errors arising from statistical variation in radioactive decay may be
132calculated readily. These counting errors, in the case of I, 
were estimated to be less than IS for uptakes greater than 5% dose.
In the case of *^ ™^Tc, the estimated error* over the same uptake range, 
was less than 2.5%. Subjects with thyroidal uptakes less than 5% 
dose were, as a rule, not studied with the uptake counter because such 
uptakes are small compared to the magnitude of extra-thyroidal 
activity.
The fact that the total random error was not estimated is of no 
practical disadvantage, A facility of the present method of analysis 
is that sample variance can be calculated from the observed data 
(Section 2.4.). This enables parameter errors to be determined in the 
absence of variance estimates for each data point, (Individual 
variances were not required as weighting factors, because weighting 
was considered not to be necessary (Section 3.6)).
4-. 3 The Uamma Cam era/Computer System
Use of ^^^I-iodide. Because of the relatively low energy (159 
KeV) of its principal emission and relatively short half-life
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(13*3 hours) ^^^I-iodide has favourable characteristics for In vivo 
imaging studies (40, 119-124). However, the material, as available, 
contains a variable proportion of impurities (125). That from the 
MRC Cyclotron Unit (Hammersmith Hospital), which was used In the 
present work, contained comparatively high proportions of impurities 
at the time of production; 3% 4.2 days), 0 5^2% (T^ 51.4
days) and 0.24% ^^I(T^ 13 days) (126). Because of transport 
difficulties, the material could not be used until the day following 
production, by which time the proportions of and
increase to 11%, 2.4% and 1.2% respectively. These impurities increase 
the radiation dose to the thyroid by a factor' of 10, but even so the 
dose from impure ^3l-Iodide is still much less than that from ^31%^ 
iodide (150 mrera/uCi compared to 1300 mrem/uCi) (117). However
123
because the radiation dose is not inconsiderable, the amount of I- 
iodide given to each subject was restricted to 150 uGl,
The presence of impurities - in particular ^^4% which emits 
photons of energy 510 and 600 KeV - caused some further inconvenience 
as far as imaging with the gamma camera was concerned. Exploratory 
studies of a thyroid phantom revealed that, even with a high energy 
(400 KeV) collimator, significant counts were found outwith the thyroid 
image, as defined by the principal radiation of This is the
result of penetration of the collimator by the high energy photons 
from the ^^4% contaminant. Other workers (124, 127-128) have reported 
similar degradation of image quality.
In practice, the net effect was that the region chosen for 
calculation of room background and extra-thyroidal activity, in the 
patient study, contained a contribution from activity in the thyroidal
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area. Likewise in the calibration study, when a standard was assayed 
within the thyroid phantom, the area chosen for calculation of room 
background contained similar additional counts. Studies of the 
phantom revealed that these additional counts amounted to approximately 
6% of the thyroidal counts. However, it was considered that if the 
background regions are similarly placed with respect to the thyroidal 
area, the spill-over fractions in patient and phantom are likely to 
be equal. Any systematic error in the calculation of thyroid uptake, 
resulting from collimator penetration of the photons from the 
contaminant, may thereby be minimised.
Choice of background area. Essential to the measurement of 
thyroidal uptake using a gamma camera, is the selection of a suitable 
background area in the scintigraph from which extra-thyroidal activity 
in the thyroidal area may be estimated. Some workers have chosen an 
area immediately inferior to the gland (85, 106, 108-111), while 
others have chosen areas both inferior and superior to the gland (40, 
46, 51). As a rule, the choice of background area in these studies 
was based on studies of athyreotic subjects, or of subjects given 
perchlorate to block thyroid uptake.
Recently, Armstrong et al (46) have suggested that, in thyrotoxic 
subjects, the gland may be much more vascular than those adjacent 
tissues normally used in the estimation of extra-thyroidal activity. 
They considered that activity of ^^’^Tc-pertechnetate in the thyroidal 
area, which was not true uptake, could as a result be seriously 
underestimated; in other words thyroid uptake could be overestimated. 
It is not clear, however, whether any background studies had been 
undertaken in thyrotoxic subjects who had received a blocking dose of
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perchlorate. In view of tkis, the present work included some 
further studies of tissue radioactivity in the neck region, when 
thyroidal uptake was absent, in a group of subjects of varying thyroid 
status.
Five subjects were investigated, 2 were thyrotoxic, 1 was
euthyroid and the remaining 2 were athyreotic. The first 3 were given 
99m
Tc-pertechnetate intravenously, a few minutes after an intravenous
blocking dose of 600 mg sodium perchlorate (Section 3.8); the last
2 received ^^^I-iodide but did not require perchlorate. Radioactivity
in the neck region was monitored continuously on the gamma camera/
computer system for at least 15 minutes. Data were integrated over
successive periods of either 30 seconds, in the case of or 120
123seconds, in the case of I, and recorded on magnetic tape. At 
analysis, several background areas were compared with the thyroidal 
area, after correcting for non-uniform camera response.
The most satiafactory background area was one of approximately 
one third of the size of the thyroidal area. It lay just inferior to 
the gland and was slightly displaced relative to the mid-line, away 
from the site of administration of the tracer. The eccentric position 
of this background area meant that very little of the image of the 
injection bolus, as it passed through the appropriate subclavian vein 
(129), was included. This area gave the best correspondence with the 
thyroidal area, especially in the period immediately after administration 
of the tracer.
The similarity between counts in the thyroidal and background 
areas is shown by the results presented in Table 10, All counts have 
been normalised to the same area (that of a normal thyroid image) and
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expressed as a percentage of the administered dose. As can be seen, 
the background area provides at all times, except the earliest, an 
estimate of the activity of the thyroidal area to within 0,5% dose. 
Observed differences at any time, in the data as a whole, are not
I
significant (p>0,05) by the Student t test for pair differences (80),
It is of interest to note that, even in the thyrotoxic subjects,
the background was satisfactorily estimated. This casts doubt upon
the deductions of Armstrong et al (4-6) with regard to the relative
vascularities of the thyroid gland and adjacent tissues.
Method. Use is made of two different parallel hole collimators,
a low energy, high resolution one for'^ *^ T^c studies and a high energy
(4-00 KeV) collimator for studies. Energy intervals of 110-170
KeV and 130-190 KeV are chosen for ^^^Tc and ^^^I respectively. The
subject is placed in the supine position with the gamma camera at 12 cm
99m
from the neck. A dose of 1 mCi Tc-pertechnetate, or 150 uCi 
123
I-iodide, in a volume of 5 ml isotonic saline, is injected into
the antecubital vein and the changes in neck radioactivity monitored
using the gamma camera/computer system. The study is continued for
either 60 minutes, or 90 minutes, if a perchlorate discharge test
is required (Section 3.9). At the end of the study, an aliquot of the
administered dose is placed in a neck phantom (Section 4.2) and data
recorded for a few minutes.
For ^^^c, data are integrated over successive periods (frames) of
30 seconds, starting at the time the tracer is given. However, because
of restriction on the administered dose, the frame time for ^^3% %g
123120 seconds. Recording of the data in the case of I is delayed
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by 30 seconds to avoid possible problems in estimating extra- 
thyroidal activity in the first frame, (Exploratory studies revealed 
that, even with the background area placed eccentrically, there could 
be a significant contribution from the injection bolus)*
The first step in the analysis programme is correction of each 
data frame for non-uniform response of the camera. This makes use 
of the image of a uniform flat source of *^”^^Tc-pertechnetate. Counts 
in each frame, attributable to thyroid uptake, are then determined from 
the thyroidal area, after subtracting the normalised extra-thyroidal 
counts. Thyroid uptake, in terms of percent administered dose, is 
calculated using the net standard counts from the phantom study, with 
appropriate correction for radioactive decay. The time of each 
measurement is considered to be the time from administration of the 
tracer to the mid-point of the data frame.
Counting errors. As in the case of measurements with the uptake 
counter only counting errors due to statistical variation in source 
count rate were calculated. These errors were estimated to be less 
than 4% and less than 1.5%, respectively, for ^^^I-iodide and ^^’^Tc- 
pertechnetate uptakes of greater than Z% dose. Because of the lower 
contribution from extra-thyroidal activity, the gamma camera was the 
instrument of choice when thyroidal uptake was low. Thus errors 
were calculated for a wider range of uptakes than in the case of the 
uptake counter.
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CHAPTER FIVE
COI'a^ ARTMENTAL ANALYSIS OF IODIDE AND PERTECHNETATE UPTAKE
5.1 Introduction
The review of published work in Chapter 1 has revealed short­
comings in previous compartraental analysis of iodide or pertechnetate 
uptake by the thyroid gland. Of considerable importance is the wide 
variation reported for the binding rate of iodide in the uninhibited 
gland (Table l). Another feature is the virtual absence of information 
about the precision to which the various parameters were estimated.
The studies of Gray (Section I.IO) have gone some way towards 
explaining the wide range of binding rate estimates for iodide. His 
innovation was to use arterial radioactivity levels, rather than venous 
levels, in the calculation of clearance (Section 1.4). With that 
modification, the clearance of radioiode in the uninhibited gland was 
found to be constant with time, thus suggesting that the binding rate 
is much greater than the exit rate. Further indication that the 
binding rate is relatively high, i.e. at the upper limit of the range 
of reported values, emerges from his failure to detect dischargeable 
radioiodide at the early time of 10 minutes after administration of 
the tracer. However, the analysis employed in Gray's studies relied 
on graphical techniques and was subject to errors of human judgment.
It would seem appropriate, therefore, to determine whether the findings 
are supported by improved digital analysis.
The method of analysis developed in the present work includes a 
correction for arterio/venous differences in plasma radioactivity levels
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(Section 3.2) and also provision for the estimation of random errors 
(Section 2.4). Reported in this chapter is the outcome of applying 
the method to the results of simultaneous studies of iodide and 
pertechnetate uptake. A principal objective was to test whether 
"least sum of squares" analysis would produce results which were 
consistent with the findings of Gray concerning the binding rate of 
iodide. Furthermore it was hoped that the technique would be 
sufficiently sensitive to quantify, in terms of binding rate, the 
small extent to which pertechnetate is organified (3-7). The 
analysis would also allow comparison, in fundamental terms,of the 
kinetic behaviour of iodide and pertechnetate.
khny of the experimental data used in this exploratory study 
Were those obtained and analysed previously by Robertson (27, 130).
The present author has simply applied an improved kinetic analysis 
to those data which, because of the relatively long observation period 
(up to 2.5 hours), are extremely valuable.
5.2 Patients and Methods
Kinetic studies of iodide were performed in 15 untreated thyrotoxic 
and 8 normal subjects. The experimental data were acquired and first 
analysed by Robertson (27,130). He used a radioisotope scanning 
technique to measure thyroid uptake after an intravenous dose of 
25 uCi ^31i-iodide. Scanning was started 30 seconds after injection 
of the tracer, with the duration of each scan being approximately 4 
minutes, and continued for up to 150 minutes. Venous blood samples 
were taken at 2, 8, 18, 35, 105 and 150 minutes. The net thyroidal 
count in each scan was obtained by subtracting an estimate of the
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tissue and room background which was based on an adjacent extra- 
thyroidal area. Comparison of this net count with that from the 
scan of a standard, placed within a thyroid phantom, allowed thyroid 
uptake to be estimated.
Fourteen of the thyrotoxic subjects and all the normal subjects 
received 1 taCi ^'^Tc-pertechnetate at the same time as the 
radioiodide. Tliyroidal uptake of perteclnetate was measured in 
exactly the same way as of the latter, except that correction had to 
be made for the contribution from to the count within the ^^ ^^ Tc
energy interval.
Studies of the shortrterm effect of the anti thyroid drug, 
carbiraazole (120 mg in divided oral doses over the 24 hours before 
the study), on thyroid uptake kinetics were also undertaken. Seven 
thyrotoxic subjects and 1 normal subject were investigated for drug- 
induced changes in iodide kinetics, and 7 thyrotoxic and 3 normal 
subjects for possible changes in pertechnetate kinetics. Investigations 
in all subjects, except 2, were carried out by Robertson (27, 130)
Using the radioisotope scanning method just described. Thyroid uptake 
of radioiodide in the remaining 2 subjects was determined by the present 
author using the gamma camera method described earlier (Section 4.3).
5.3 Analysis
As a first step in analysis of the data, an approximated curve 
of tracer concentration in arterial plasma was obtained from the 
measurements in venous plasma (Section 3*2). This entailed fitting a 
single exponential term to the venous plasma measurements from 30
— loo —
minutes onwards and then, 6y the method of curve stripping, determining 
a further exponential term to complete description of the earlier part 
of the plasma curve. The approximated arterial curve, consisting 
of 3 exponential terms, could then by derived making use of the 
factors derived previously.
In most of the cases where the study extended to 150 minutes, 
the levels of plasma radioiodide from 30 to 150 minutes lay on the 
same straight line on log-linear graph paper. However there were 4 
exceptions (all thyrotoxic subjects) where the radioiodide concentration 
at 150 minutes lay above the line through earlier points. This was 
considered to be the result of early discharge of labelled thyroid 
hormone into the circulation (Section 3.4)• Thus, to minimise error 
in analysis of these cases, the measured plasma radioactivity at 150 
minutes was excluded in estimation of the final exponential component 
of the venous radioiodide curve.
The observed thyroid uptake data were then combined with this 
approximated arterial curve and analysed on the basis of the open 
three-compartment binding model following the procedure outlined 
earlier (Section 3*9). For iodide data obtained from normal and 
and untreated thyrotoxic subjects, the minimised sum of squares with 
exit rate equal to zero was compared to the least sum of squares 
obtained without constraint on the exit rate.
Statistical analysis of the results was performed, whenever 
possible, using the non-parametric Vilcoxon rank test or the Wilcoxon 
rank test for pair differences (80). Relationships between parameters 
were tested by linear regression using the "t" statistic (80) to 
assess significance.
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5.4 Results
The variation with time of thyroidal uptake radioiodide, before 
and after carbimazole, and of ^ '^ T^c-pertechnetate is illustrated by the 
example in Figure 5.1. A close similarity was noted in all cases 
between the uptake curves for pertechnetate, where binding is minimal, 
and for iodide in the presence of antithyroid drug.
Problems were immediately encountered in analysis of radioiodide 
data from the uninhibited gland. The parameter estimates at the 
true minimum of the sum of squares function had large errors and the 
values from case to case varied markedly (Table 11), apparently due 
to lack of curvature, in exit/binding rate space, of the minimised sum 
of squares function (Figure 5.2). This lack of curvature is quantified 
in Table 12, where the minimised value, i.e. with optimum unidirectional 
clearance and initial free uptake, when the exit rate is zero, is 
compared to the true minimum value of the function. As can be seen, 
the ratio of those values in 24 untreated thyrotoxic subjects (the 
present 15 and a further 9 from studies reported in Chapter 6) and 8 
normal subjects, did not exceed 3.07. These results imply that the 
binding rate is much greater than the exit rat^ and so neither can be 
estimated reliably. It follows that the analysis can provide estimates 
only for unidirectional clearance and initial free uptake (Section 
3.7). In contrast, the sum of squares ratio for pertechnetate data, 
and for iodide data when binding was inhibited, was always greater 
than 3.07.
Results of the compartmental analysis, for both iodide and 
pertechnetate, in the 15 untreated thyrotoxic and 8 normal subjects 
are presented in Tables 13 and 14 respectively. The mean (-sd)
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THYROID UPTAKE O I  after carbimazole 
(% dose) X Tc
100-1
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Fl^ yure 5.1 Thyroid uptake curves for before and after
carbimazole, and for 99nrc in a thyrotoxic subject.
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Figure 5.2 Contour map of sum of squares function in exit/binding 
rate space (radioiodide data from an untreated thyrotoxic subject).
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TABLE 12
ANALYSIS OF RADIOIODIDE UPTAKE DATA IN NORMAL AND THYROTOXIC SUBJECTS; 
COMPARISON OF LEAST SUM OF SQUARED DIFFERENCES AND MINIMSED VALUE 
WITH EXIT RATE EQUAL TO ZERO
Patient and 
thyroid status
W.C.
R.D.
u M.R.
N D.N.
T M.H.
R M.L.
E D.McM.
A E.H,
T E.L.
E s.s.
D I.McA.
M.McL.
T I.S.
H J.McA.
Y S.McP.
R D.W.
0 M.C.
T A.McO.
0 D.K.
X M.A.
I A. Cg.
C J.J.
C.I,
M.W.
E.M.
N E.McF.
0 E.McI.
R W.K.
M C.H.
A E.McP.
L I.M.
A.W.
Least sum of 
squared differences 
,/Sl) „
% dose^
71.86
15.62
71.42
7.44
67.62
27.55
20.89
15.62
39.34 
10.27 
50.85 
23.72 
25.71 
67.15 
10.13 
15.65
5.93 
9.03 
4.68 
2.90
26.47
8.34 
0.43 
4.56
8.83 
8.25
12.44 
8.20
3.55 
4.73
4.47 
13.6o
Sum of squared 
differences with 
exit rate - 0(S2)
% dose^
107.3 1.49
23.42 1.50
75.04 1 .05
8.43 1.13
114.10 1 .69
27.61 1.00
21.87 1 .05
17.37 1.11
40.89 1 .0 4
22.80 2.22
52.29 1 .03
36.58 1.54
28.45 1.11
70.15 1 .04
13.05 1.29
23.05 1.47
10.89 1.84
15.15 1.68
10.63 2 .27
3.13 1.08
55.88 2.11
11.58 1.39
0.52 1.21
8.88 1.95
9.36 
8.53
13.79
8.32
4.83
14.50
5.36 
15.23
Ratio S2 
SI
1.06
1.03
1.11
1.01
1.36
3.07
1.20
1.12
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unidirectional clearance of iodide is 160,7-130.5 and 23.1*9.5 ml 
minute"^ in the thyrotoxic and normal group respectively. Corresponding 
values for pertechnetate are 50.6*47.0 and 9.8*3.7 ml minute"^.
The difference between the normal and thyrotoxic group for each anion 
is significant (p<0,0l). When the data from all patients are 
Combined, there is significant correlation (p<0,05) between the 
unidirectional clearances for iodide and pertechnetate (Figure 5.3).
The unidirectional clearance for iodide is greater on average by a 
factor of 3.25-2,04 (sd), but there are considerable individual 
deviations from the mean.
There is no significant difference (p>0.l) in either the exit 
rate or binding rate of pertechnetate between the normal and 
thyrotoxic subjects. In all subjects the mean (-sd) exit rate is 
0,051-0.019 minute"^ and the mean binding rate 0,0011*0.0030 minute*"^ .
The latter, in fact, is not significantly different from zero (p>0,05).
The mean (*sd) initial free uptake for iodide is 2,48-3.07 and 
0,64-1.41 ^ doSe, in the thyrotoxic and normal group respectively.
For pertechnetate the corresponding values are 3.87-4.26 and 0.77^1.02 
% dose. No significance can be attached at this stage, however, to 
these differences between normal and thyrotoxic subjects (p>0.05).
Regression analysis of the initial free uptakes for iodide and 
pertechnetate reveals a significant correlation (p<c0.05) when the 
results from all cases (except subjects W.C. and R.D. where the errors 
are exceptionally large) are combined (Figure 5.4). The apparent 
difference between the initial free uptakes of the two anions is, 
however, not significant (p>0,l), (The relationship between the inital
free uptakes of iodide and pertechnetate, and the possible relationship
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Unidirectional 
Clearance [  Tc ]  
ml minute
200-
y =  0  288x  4- 0 - 6 0 0  [ r  = 0 8 5 ]
100-
^ 0250
Unidirectional Clearance [  I ]  ml minute
Figure 5» 3 Correlation between the unidirectional clearances of 
iodide and pertechnetate in normal and untreated thyrotoxic subjects,
Initial Free 
Uptake [  l ]  
%Do^e
10-
y = = 0 - 3 2 7 x - f  0 - 7 3 0  [ r - 0 - 4 8 1
«  Initial Free U p tak e  [ T c ]  %  Dose
Figure 5.4 Correlation between the initial free uptakes of iodide and 
pertechnetate in normal and untreated thyrotoxic subjects.
between initial free uptakë and gland activity, are explored further 
in Section 6,2).
Carbimazole had no effect, in the short-term at least, pn the 
unidirectional clearance and initial free uptake of iodide (Table 15). 
Statistical analysis of the combined results from the thyrotoxic and 
normal subjects, before and after carbimazole, reveals no significant 
difference in these parameters (p>0.l). The same is true of the 
unidirectional clearance, exit rate, binding rate and initial free 
uptake of pertechnetate (p>0,l). After carbimazole, however, the 
binding rate for iodide is reduced to values that are considerably less 
than the estimated exit rate. In the 7 thyrotoxic subjects and 1 
normal subject the mean (tsd) binding rate of iodide after carbimazole 
is -0.003-0.OOS minute“Tj which is not significantly different from 
zero (p3»0.3). The mean (-sd) exit rate is 0.033-0,035 minute"^ .
5.5 Discussion
Numerical analysis of radioiodide uptake data, by the new method 
developed in this thesis, has produced results that are consistent with 
the binding rate of iodide being much greater than exit rate, in the 
uninhibited gland. The results confirm for the first time, by "least 
sum of squares" analysis, the finding of Gray (28) that the net 
clearance of radioiodide, in normal and thyrotoxic subjects,is virtually 
constant and equal to the unidirectional clearance. As in Gray’s 
technique, the present method of analysis includes a correction for 
arterio/venous differences in plasma tracer levels.
Evidence for the constancy of radioiodide clearance lies in the 
occurrence of least sum of squares solutions with large errors due to 
lack of curvature in the sum of squares surface. Thus, when the
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minimised sum of squares value, vith the exit rate equal to zero 
(constant clearance condition), uas compared vith the least sura of 
squares, the former vas never more than 3,07 times greater in 24- 
untreated thyrotoxic and B normal subjects. This is in keeping 
vith earlier considerations of the analytical problems that might arise 
if the binding rate is much greater than the exit rate (Section 3.7). 
Under such circumstances the analysis can provide only estimates of 
unidirectional clearance and initial free uptake. Neither binding 
rate nor exit rate can be estimated reliably, since all values of 
these parameters, vithin certain limits, produce almost identical fits 
to the observed data.
A means of quantifying the binding rate of iodide in the 
uninhibited gland vas discovered, unexpectedly, in the perchlorate 
discharge studies reported later (Section 6,i). In one exceptional 
cane, an untreated thyrotoxic subject, there vas a discharge of 7.5% 
of the radioiodide uptake at 30 minutes. The binding rate for that 
subject vas estimated to be 0.150 minute"^, using a method based on 
the observed discharge by perchlorate (Section 6.3 and Appendix 2).
This serves, therefore, as an estimate of the lover limit of binding 
rate in normal and untreated thyrotoxic subjects.
A lover limit for the effective clearance of stable iodide 
(Section 2.7), in terms of unidirectional clearance, may also be 
determined for the uninhibited gland. This requires an estimate of 
exit rate vhich, for present purposes, may be taken to be the mean 
value (0.04.6 minute )^ in all subjects studied vith inhibited binding 
(Table 22, Chapter 6). The limit is 75% vhich is readily determined 
from the expression 100 Kg/(N^p+E^) (Section 2,7) or from Figure 5.5
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EFFECTIVE
CLEARANCE
[%]
1001
501
0 50-40 1 0*2 0 30
BINDING RATE minute-1
Fleure 5,5 Variation of effective iodide clearance (as a percentage 
of unidirectional clearance) with binding rate, a value of 0,0^6 minute 
being taken for the exit rate.
where effective clearance versus binding rate is plotted* Thus the 
present work suggests that,when there is no inhibition of binding»
75-100of the iodide entering the gland is eventually organified.
In contrast to the results for iodide, the mean binding rate of 
pertechnetate (0,0011 minute*"!) in both normal and thyrotoxic subjects 
was not significantly different from zero. It would appear, therefore, 
that because of experimental errors the small extent to which 
pertechnetate is organified cannot be quantified reliably by the 
present technique. The estimated values indicate only the order of 
magnitude of the binding rate.
The mean unidirectional clearance of iodide and pertechnetate 
was found to be lower in normal subjects (23*1 and 9.8 ml minute"^ 
respectively) than in thyrotoxic subjects (l60,7 and 50.6 ml minute"^ ). 
On the other hand, the exit rate of ion from the gland would seem to 
be independent of thyroid status, as can be deduced from the results 
for pertechnetate. These findings, which merely confirm previously 
reported work (Table 1), suggest that the greater uptake of both ions 
in the thyrotoxic state (27, 116) is a consequence of greater blood 
flow and trapping, and not of reduction in leakage of trapped material. 
(Evidence to be discussed later in Section 6.2 suggests that the exit 
rate in individual subjects may have some dependence upon unidirectional 
clearance),
Whilst the unidirectional clearance of iodide in normal and 
thyrotoxic subjects was greater than that for pertechnetate (by a 
factor of 3.25 on average), the same was not true of the initial free 
uptake. The observed data suggested that the initial free uptake for 
pertechnetate was at least as great as that for iodide. However, if,
— io 6  "»■
as Indicated earlier (Section 3*3)> the initial free uptake is the 
fraction of the injected bolus of tracer that is trapped by the 
thyroid, that parameter should have been greater for iodide on the 
basis of greater unidirectional clearance. In view of this inconsistency 
between observed and expected results, the phenomenon of initial free 
uptake, and its relationship to unidirectional clearance, was studied 
further and the outcome is reported in Section 6,2,
The relationship between the unidirectional clearance for iodide 
and that for pertechnetate merits some further comment. Other workers 
(Table 1) have reported iodide/pertechnetate clearance ratios of 
1.4.-2.4-, which are lower than the present value of 3.25^.04 (sd).
These discrepancies can be explained by differences in analytical 
technique and by the fact that the relative affinity of the gland for 
the two ions may vary markedly from patient to patient. (In a further 
6 thyrotoxic patients studied (Section 6,2), the mean iodide/pertechnetate 
clearance ratio was 1.71^,50).
Carbimazole (120 mg in divided doses over 24 hours) was found to 
affect only the binding of iodide, which was reduced to negligible 
levels. This meant that exit rate could be estimated, (The exit rate 
estimates are combined with additional results in Section 6,2 to obtain 
a grand mean in all subjects studied in the present work). Any 
possible effect on the binding of pertechnetate would certainly have 
been beyond the limits of detection of the analysis technique. There is 
no evidence from the results to support the finding of Robertson (2?) 
that carbimazole may increase both unidirectional clearance and exit 
rate,
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CHAPTER SIX
CONTROL OF THYROTOXICOSIS WITH MTITHYROID DRUGS
6.1 Introduction
The thiocarbamide drugs, namely, methimazole, carbimazole and 
propylthiouracil, have an important role in the treatment of 
thyrotoxicosis, particularly in the younger patient (131-133). These 
drugs prevent the biosynthesis of thyroid hormone by inhibiting, firstly, 
the formation of monoiodotyrosine and diiodotyrosine and, secondly, 
the coupling of these iodotyrosines to form the iodothyronines, T^, and 
T^ (9, 86, 134, 135). Thus treatment with thiocarbamide drugs results 
in reduced levels of circulating thyroid hormone; a euthyroid clinical 
state being achieved, usually, within 4"^ weeks from commencement of treat­
ment (9 ,136)* However, to minimise thé risk of hypothyroidism, the dose of 
drug is usually not sufficient to completely inhibit organification of 
iodide (137, 138). There is no clear evidence to suggest that 
antithyroid drugs have a direct effect on the underlying disease process 
(132, 135, 139) and treatment is continued for 12-24 months in the hope 
that remission of the disease will occur spontaneously during therapy
(131, 133).
Most studies have shown that, in approximately 50% of patients so 
treated, thyrotoxicosis either continues or recurs, usually within 2 
years of completing treatment (I3I, 132, 136, I38, 140). In one study, 
however, the failure rate was approximately 80%, but this was thought 
to be due to an increased iodine intake in the population under
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investigation (141)• Long-term remission of the disease occurs in 
the remainder but, in a proportion of these, some abnormality in 
thyroid function may still exist at a subclinical level (139, 142), 
Recurrence of the disease has been observed in an occasional patient 
as long as 22 years after a first course of antithyroid drug therapy 
(140).
As yet, no way has been found of determining, before anti thyroid 
drug therapy commences, whether the subject will remain euthyroid or 
relapse after therapy. However, limited success has been achieved in 
predicting the outcome of treatment, once it has started, by observing 
various aspects of thyroid function. The likelihood of long-term 
remission has been found to be greater where there is a reduction in 
goitre size (14-3-14-5). Remission is also more likely if there is a 
return to normal suppressibility of uptake by the action of exogenous 
hormone (112, 116, 133, 140, 146-151), or if there is a spontaneous 
reduction in thyroid uptake (138, 152). On the other hand, if the 
blood level of thyroid stimulating immunoglobulin remains high, there 
may be a greater risk of relapse (153, 154).
It is particularly important to recognise,as early as possible, 
those patients who are destined to have persistent disease so that 
destructive therapy can be arranged with as little delay as possible.
In an interim plan for treatment of thyrotoxicosis, McLarty and 
Alexander (140) change to destructive therapy if, after 6 months 
treatment with antithyroid drugs, the 20 minute radioiodide uptake has 
either risen, is above 30%^or cannot be suppressed by T3 to 50% of the 
control value, Goolden et al (138) found the 20 minute uptake of 
^^Tc-pertechnetate during the first 6 months of treatment to be of 
limited value, but found that failure to achieve a normal uptake at the
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end of treatment indicated 'impending relapse. It may well be that if 
all relevant parameters, including immunological and biochemical factors, 
were considered together, better prediction of the results of antithyroid 
drug therapy might be possible (14-6).
In view of the continuing use of early iodide and pertechnetate 
uptake in the assessment of thyroid function during antithyroid drug 
therapy, the present work included some detailed studies of the uptake 
kinetics of these two anions in thyrotoxic subjects receiving drug 
treatment. These studies were intended to serve as an extension to 
previously reported work on the subject (115,116).
There were a number of objectives. In particular, kinetic analysis 
Would provide hitherto unknown information about those parameters which 
describe the trapping and binding functions of the gland, during the 
course of drug-treated thyrotoxicosis. It was hoped that these 
parameters might be useful in predicting the outcome of therapy. 
Furthermore, there was a need to explain some interesting differences in 
the behaviour of the two anions, such as variability in relative uptake 
with the occurrence of uptake values for pertechnetate that sometimes 
exceed those for iodide (155). Another problem considered was that 
of occasional resistance to antithyroid drugs due to a lower than normal 
inhibition of iodide organification (156). Some observations were also 
made of the short-term response to varying doses of drug. The object 
was to find the smallest dose necessary for control of the disease - 
a factor that is important in the treatment of the pregnant thyrotoxic 
patient when placental transfer of the drug (157) should be minimised. 
Possible long-term effects of antithyroid drugs on the binding function 
of the gland were also investigated.
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6.2 Iodide and Pertechnetate Kinetics in Long-Term Antithvrold Drug
Therapy
patients and Methods. Six previously untreated thyrotoxic 
subjects were selected for the simultaneous study of iodide and 
pertechnetate during routine drug therapy (133)• Five were treated 
with carbimazole (30-40 mg d“  ^initially, reducing to 15-20 mg d )^ and 
T3 (80 ug d"^), Drug therapy was discontinued after-4-12 months but 
patients continued to receive T3. The remaining subject received only 
propylthiourucil, in an initial dose of 400 mg d”"^  reducing to 100 mg
d-b
Thyroidal uptake of intravenously administered ^^^I-iodide and
.Tc-pertechnetate was estimated using an uptake counter, adhering to 
the procedure described earlier (Section 4.2). Samples of venous 
blood, for estimation of plasma radioactivity, were taken at appropriate 
times after the administration of the tracers (Section 3.9). Each 
subject was investigated before and at various times during the course 
of therapy. There were at least 3 investigations within the first 
6 months of treatment, but the frequency was less thereafter. A 
perchlorate discharge test (Section 3.9) was introduced later as an 
additional procedure in the investigation of each subject.
Repeated studies of the kinetics of ^ *^’^Tc-pertechnetate alone 
were performed in one further thyrotoxic subject who was treated with 
carbimazole and T3. Thyroid uptake was measured using a gamma camera 
(Section 4.3) but the remaining aspects of the study were as for the 
other subjects.
Data were analysed, as described previously (Section 3.9), to 
provide estimates of the various parameters of the open three- 
compartment binding model of the thyroid gland. Analysis of the
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perchlorate discharge phase (Section 2,6.) permitted results from the 
uptake phase to be verified* Statistical analysis of the results 
was performed using non-parametric methods, whenever possible, as in 
Section 5.3.
Results. Because the longest period of observation in the 
present work was only 30 months, it was not possible to finally classify 
the response to therapy after the fashion of Alexander et al(133)#
They studied patients for at least 4 years from the start of treatment. 
Thyrotoxicosis was found in their experience to follow one of three 
courses:- (a) remission of the disease after one course of antithyroid 
drugs, (b) continuance or recurrence of the disease, and (c) remission 
of the disease after two courses of antithyroid drugs. The following 
clinical summary of the subjects studied in the present work can be 
Considered only as an interim report.
Two subjects (D,K. and M.C. in the results tables to follow) were
still in remission 12 and 24.5 months, respectively, after a first
course of antithyroid drugs. Only time will tell whether the disease
in these subjects will follow course (a), (b), or (c). In one of
these cases (D.K.) the 20 minute uptake of ^^^I-lodide had suppressed
into the normal range ( <  8%) on the last day of treatment, but in the
other (M.C.) the uptake was still elevated. Four subjects (A.McG.,
A.C., D.W. and M.A.) relapsed 0-11 months after therapy and a second
course of antithyroid drug therapy was commenced. All of these subjects
132had an elevated uptake of I-iodide on the last day of the first 
course of treatment. In these four subjects the disease may eventually 
follow course (b) or (c). The last subject (S.D,) had not completed 
a first course of antithyroid drug therapy when the present results 
were computed.
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Thyroid uptake curves for both ^32j and ^^ ^^ Tc at various times 
during the period of observation are shown in Figure 6,1 for each of 
the subjects who received both tracers. Similar data are given in 
Figure 6,2 for the one subject who received only ^ ^^Tc-pertechnetate,
In most cases the iodide curves, once treatment had started, can be 
seen to be similar to the pertechnetate curves, having reached a 
maximum value before 60 minutes. However, in the case of subjects 
A.McG, and M.C, the pattern is one of continuously increasing radioiodide 
uptake off or on treatment.
Results of the kinetic analysis along with the clinical and 
biochemical response to therapy are presented for each subject in Table 
16. These results comprise estimates of unidirectional clearance, 
exit rate and initial free uptake for iodide and pertechnetate, and 
estimates of binding rate for iodide. Included also are the estimated 
20 minute uptakes of the two tracers and estimates of the free thyroxine 
index (158).
In terms of immediate response to therapy the most relevant 
result is the observed reduction in binding rate of iodide from a 
pre-treatment value of >  0,150 minute  ^to a mean value (-sd) for all 
subjects of 0.009—0,007 minute""^  during treatment. The effective 
clearance of iodide (Section 2,7) is thereby reduced from >75% (Section 
5.5) to a mean value (-sd) of 17.6^14.5% of the unidirectional 
clearance (Table 17). Both the mean binding rate and effective 
clearance of iodide during drug therapy are significantly greater than 
zero (p<0,05).
Subject A.McG, has the lowest exit rate and subject M.C. the 
greatest binding rate of iodide during therapy. This may explain the 
failure of radioiodide uptake in those two cases to reach a peak value
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Figure 6.1 Thyroidal uptake variations of iodide and pertechnetate
in antithyroid drug therapy.
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Figure 6.1 cont*d
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F ig u re  6^1 cont*d
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•e 0.4 Thyroidal uptake variations of pertechnetate in anti thyroid 
drug therapy. (Subject S.D. did not receive radioiodide tracer).
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TABLE 17
EXIT AND BINDING RATES, AND EFFECTIVE CLEARANCE OF IODIDE DURING
ANTITHYROID DRUG THERAPY
Subject Mean exit 
rate (itge)
Mean binding 
rate (*se) 
inln 1
Mean effective, 
clearance (*se) 
%
M.C., 0.062t0.015 0.023*0.009 27.0^9.1
M.A. 0.0 2 7 ^ .0 0 6 0.004*0.002 12.0ié.7
D.V. 0.04# 0.006 0.010*0.002 19.0*3.0
A.McG. 0.01>to.003 0.006*0.002 30.2*9 .4
A.C. 0.077+0.008 0.009*0.001 10.1*1.7
D.K. 0.027*0.006 0.002*0.002 8.2±7.1
Mean (%d) 0.042*0.025 0.009*0.007 17.6*14.5
as a percentage of midirectional clearance
before 60 minutes, during therapy (Figure 6,1), In spite of 
manifesting a relatively high uptake of ^^^I-iodide, after antithyroid 
drugs vere discontinued, subject M.C, remained clinically euthyroid. 
Triiodothyronine vas also discontinued of the subject^s own accord. 
Concurrent estimates of plasma inorganic iodide (159) revealed 
abnormally low values, which suggested a state of iodide deficiency and 
hence greater uptake of radioiodide.
Some validation of the binding rate estimates for iodide during 
therapy is provided by the results given in Table 18. Shown there are 
the results of the perchlorate discharge tests in the present group of 
thyrotoxic subjects, combined with similar results from those other 
subjects with inhibited organification of iodide, studied in the 
present work. Analysis of the uptake phase of the studies provided 
estimates of the fraction of uptake that would be discharged by 
perchlorate (Section 2.6) and these are compared in the table with the 
observed values. In fact, the binding rate largely determines, these 
dischargeable fractions (Section 6.3), The 'mean computed 
value (* sd)> 60.0*29.7^, in 19 subjects is not significantly 
different (p> 0.1) fi*om the mean observed value, $8,9*25.8%.
Thus although there may occur substantial discrepancies
in individual cases, the kinetic analysis seems to provide a reliable
estimate of the mean binding rate of iodide in a group of subjects,
A similar comparison is presented for pertechnetate in Table 19, 
but statistical analysis reveals a significant difference (p<G.G5) 
between the mean computed dischargeable fraction (*sd)., 77.0*9.0%, 
and the observed value, 92.5*6.5%, in the seven subjects studied.
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TABLE 18
PROPORTION (%) OF RADIOIODIDE UPTAKE DISCHARGED BY PERCHLORATE 
AT 60 MINUTES; COMPARISON OF OBSERVED AND COMPUTED VALUES IN 
SUBJECTS WITH DEFECTIVE BINDING DUE TO DRUGS OR DISEASE
Subject Observed discharge 
(*se)
Computed discharge 
(-8^ %
M.A. 78.6^2.3 80.8*16 .0
D.V. 54.2*1.5 40.3i 5.4
A.McGa 75.9*4 .9 53.7*11.9
A.C. 69.1*3 .9 46.9*4*2
- D.K. 83.7*3.0 89.0*16.5
P.Y. 85.3*0.9 86.8*17.5
M.D. 47.0*18.1 57.7422.5
s.v. 11.0*0.5 13.8±5 .0
W.McG. 52.3*0 .6 49.5*3.0
F.McT. 39.0*4.4 86.6*26.8
L.McL. 98.1*0.5 69.9*6 .6
M.S. 64.8*2 .5 64.3*7 .5
JA.S, 11.0*0.4 15.7*3.3
B.S. 25.2*0 .7 17.7*4 .6
MY.S, 29.5*0 .9 30.8*3.1
J.J. 71.2*2.4 50.1*7 .9
G.I. 81.3*1.6 62.6*7.0
C.McI. 81.1*2.6 105.5*2 4 .4
M.W. 62.4*4.3 118.4*37.0
Mean (&sd) 58.9*25 .8 60.0*29 .7
TABLE 19iu ilaumV
BINDING RATE AND PROPORTION (%) OF ‘^'^c-PERTSCHNETATE UPTAKE 
DISCHARGSD BY PERCHLORATE AT 60 MINUTES IN THYROTOXIC SUBJECTS; 
GOI'iPARISON OF OBSERVED AND COMPUTED VALUES OF THE LATTER.
Subject Binding rate 
(±se) 
mln-l
Observed 
discharge (*se) 
%
Computed 
discharge (*se) 
%
M.C. 0.005*0.001 95.2±12.7 73.645.2
M.A. 0.003*0.002 82.21 3.5 80.9*8.5
D.W. 0.003*0.001 89.81 6.5 38.3*12.1
A.McG. 0.004*0.001 96.4*2.8 77.3*3.2
A.C, 0.004*0.001 87.1*3.9 70.213.0
D.K. 0.002*0.001 101.417.4 89.0±7.7
S.D, 0.007*0.001 95.II0 .8 65.0*4.4
Mean(*sd) 0.004*0.002 92.516.5 77.8*9.0
This suggests that the estimated binding rate for the group (-sd), 
0,0 0 4 ^ .0 0 2 minute” ,^ is too large by a factor of approximately 3*
(The individual values for binding rate given in Table 19 are the means 
of all the estimated values for each subject. There vas no significant 
difference (p>0.l) betveen the estimated binding rates for pertechnetate 
on and off antithyroid drugs).
Figure 6.3 shows the variation of unidirectional clearance and 
20 minute uptake of iodide and pertechnetate, along with the free 
thyroxine index, during the course of management of each subject. The 
pattern of change is basically the same for each anion; both 
unidirectional clearance and 20 minute uptake being greater in the case 
of iodide. However, in subjects D.K, and A.McG-. there are occasions 
when the uptake of pertechnetate exceeds that for iodide. As a rule both 
unidirectional clearance and 20 minute uptake decrease or remain constant
with time, unless there is clinical relapse off antithyroid drugs, or 
an increase in plasma concentration of thyroid stimulating hormone 
(TSH) , as in subjects S.D. and D,W, (Subject S.D. had just suffered 
a severe domestic crisis before the final investigation and there was 
doubt as to whether T3 was being taken as prescribed. Subject D.W. 
did not receive T3.) In subject A.McG. there is discrepancy between 
the changes in unidirectional clearance and those in 20 minute uptake.
Histograms of the 60 minute/20 minute uptake ratios for 13^1- 
iodide on and off antithyroid drugs are compared in Figure 6,4; the 
results for all subjects being combined. More than 95% of the 
values during therapy are ^ 1.33, whilst in the untreated state the 
range is 1,42-2,22. Estimation of the 60 minute/20 minute uptake ratio 
or radioiodide would seem to be a possible method of checking whether
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Figure 6.3 Changes in unidirectional clearance and 20 minute 
uptake of iodide and pertechnetate, and in the T4 index, in antithyroid 
drug therapy.
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Figure 6.4 Histograms of the 60 minute/20 minute uptake ratios of 
radioiodide in thyrotoxic subjects on and off antithyroid drug 
therapy.
the prescribed antithyroid 'drug is being taken.
Correlation In the group of subjects as a whole between the 
unidirectional clearances, 2Q minute uptakes and exit rates for iodide 
and pertechnetate is demonstrated In Figures 6.5-6.7, respectively.
There is a good linear relationship (p<0,00l) between the unidirectional 
clearances for the two anions (Figure 6.5), with the clearance for 
iodide being greater by a factor of 1.71*0.50 (sd) on average. The 20 
minute uptakes for iodide and pertechnetate, whilst the subjects were 
receiving antithyroid drugs, are similarly well correlated (p<0.00l) 
(Figure 6.6), with the uptake for iodide being on average 1.25*0.27 
(sd) times greater. There is also linear correlation (p<0.00l) 
between the exit rates for iodide and pertechnetate (Figure 6.7), but 
there are considerable individual deviations from the best-fit line,
Tlie exit rate for pertechnetate is on average 2.22*1.26 (sd) times 
greater than that for Iodide.
Some attempt was made to obtain relationships between the various 
parameters describing the behaviour of each anion. Figures 6.8 and 
6.9 are plots of 20 minute uptake versus unidirectional clearance for 
iodide (on antithyroid drugs) and pertechnetate, respectively; the 
results for all subjects being combined. As can be seen there is 
significant linear correlation (p<0.00l) between these two parameters 
for each anion, but there is considerable scatter about the best-fit 
lines. Relationship between initital free uptake and unidirectional 
clearance, when the subjects were clinically euthyroid (under the action 
of the antithyroid drug), is shown in Figures 6.10 and 6.11 for iodide 
and pertechnetate, respectively. In the case of iodide there is good 
linear correlation between the two parameters (p<0,00l) with
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the best-fit line -virtually passing through the origin. There is 
also linear correlation (p<0.00l) between the initial free uptake and 
unidirectional clearance for pertechnetate, but the best—fit line does 
not pass through the origin. The reason for this is evidently the 
occurrence of substantial initial free uptake when the estimated 
clearance is relatively low.
Figure 6.12 is a combined plot of the initial free uptakes for 
iodide versus those for pertechnetate when the subjects were clinically 
euthyroid. There is good linear correlation between the two parameters 
(p<0.001) but the best-fit line fails to pass through the origin due 
to there being substantial Initial free uptake of pertechnetate, when 
the iodide value is low. The mean initial free uptake for pertechnetate 
is approximately twice as great as that for iodide.
The reason for dealing separately with the initial free uptake 
whilst the subjects were clinically euthyroid, is apparent from the 
results plotted in Figure 6,13. Shown there is the variation with 
time of the mean initial free uptake of iodide and pertechnetate during 
drug therapy. Statistical analysis shows that after 2-4. months therapy 
the values for both iodide and pertechnetate are significantly greater 
(p<0.05) than before treatment commenced. (Even after 1 month the 
values are greater, but the difference is not significant.) By these 
times all subjects had become clinically euthyroid under action of the 
antithyroid drugs.
In certain cases there is positive linear correlation between exit 
rate and unidirectional clearance (Table 20). Subjects M.C., D.W., 
A.McG. and S.D. manifest this relationship for pertechnetate (p<0.02) 
and subjects D.W. and A.McG. for iodide (p<0.02).
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YABIiS 20
STATISTICAL ANALYSIS FOR POSITIVE LINEAR CORRELATION HETOEN EXIT 
RATE AND UNIDIRECTIONAL CLEARANCE IN THYROTOXIC SUBJECTS
Subject
Iodide
Significance
level
Pertechnetate
Significance
level
M.C, P>a.3 p< 0.001
M.A. p>0.2 p>0.2
D.W. p<0.02 p<0.001
A.McG. p <0.001 p<0.02
A.C. p>0.1 p>0,l
D.K. p>0.5 p>0.1
S.D. - p <0.005
Mean exit rates from'the uptake phase in each subject are 
compared in Table 21 with the mean values obtained during perchlorate 
discharge. Perchlorate increases exit rate significantly (p<O.Ol), 
by mean factors (tgd)of 3.42-2,25 and 4.23^2,98 for iodide and 
pertechnetate respectively. (The results for iodide are combined 
in Table 22 with those from all other subjects studied In the present 
work.)
Discussion. These serial kinetic studies have provided, for the 
first time, detailed information on the thyroidal uptake kinetics of 
iodide and pertechnetate during routine drug treatment of thyrotoxicosis, 
The results show that the course of drug-treated thyrotoxicosis is 
quite variable, and that there is no clear association between the 
parameters of the three-compartment model and the final outcome of 
therapy. There are insufficient data to confirm whether the likelihood 
of remission is greater when T3 suppression of uptake or unidirectional 
clearance is achieved (112, ll6, 133, 140, 146-151). Furthermore it 
cannot be argued from the results that failure to achieve a normal 
uptake of iodide or pertechnetate is suggestive of impending relapse 
(138, 152). Thus the studies have not fulfilled earlier expectations 
that detailed kinetic analysis would provide better prediction of long­
term response to antithyroid drug treatment. However the work is 
of considerable value because it provides further information on the 
short-term response to antithyroid drugs and on the relative behaviour 
of iodide and pertechnetate.
Carbimazole and propylthiouracil in the usual therapeutic dosage 
were found to reduce the binding rate of iodide to less than 6^ of the 
value in the uninhibited gland. As a result the effective clearance 
(Section 2.7) was reduced from 75-100# of the unidirectional clearance
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TABLE 22
EXIT RATE OF IODIDE BEFORE AND AFTER PERCHIDRATE IN SUBJECTS 
WITH DEFECTIVE BINDING DUE TO DRUGS OR DISEASE
Subject Exit rate (-se) 
before perchlorate 
min-1
Exit rate (*se) 
after perchlorate 
min”*
M.C, 0,062t0.015
M.A. 0.027^0.006 0.079*0.013
D.W, 0.04210.005 0.075*0.011
A.McG. 0.013*0.003 0 .091*0.010
A.C. 0,077*0.008 0.108*0,009
D.K. 0.027*0.006 0.108*0.011
D.N. 0.030*0.010
A.McL, 0,017*0.003 —
J.McA. 0.116*0.023 —
R.D. 0.041*0.011 —
W.C. 0.014*0.009 am
p.Y. 0.019*0.003 0.088*0.004
M.McM. 0.010*0.006 0.049*0.008
E.K. 0.014*0.006
J. J. 0.118*0.010 0.142*0.010
C.I. 0.068*0.006 0.130*0,019
M.W. 0.008*0.001 0.062*0.006
J.McI. . 0,024*0 .004 0.094*0.016
M.D. 0.018*0.006 0.127*0,009
M.S. 0.060*0.007 0.116*0.016
B.S. 0.053*0.005 0.061*0,018
KY.S. 0 .069*0.006 0.139*0.018
JA.S. 0 .027*0,003 0.095*0.016
W.McG. 0.077*0.006 0.107*0.007
F.McT. 0.054*0.018 0.142*0.050
L.McL. 0.121*0.016 0.245*0.007
S.W. 0.040*0,005 0.116*0.030
Mean (^ sd) 0.046*0.031 0.109*0.040
to a mean value of 17.6# during drug therapy. There was good 
agreement, on average, between the predictions of the kinetic analysis 
for iodide and the observations after perchlorate. The fact that 
both binding rate and effective clearance of iodide were significantly 
greater than zero support the accepted view that antithyroid drugs, in 
usual dosages, do not completely inhibit binding (137, 13&).
Since there is some degree of inverse relationship between the two 
parameters (Section 2.7), any reduction in exit rate would increase 
effective clearance. This probably explains the resistance to anti­
thyroid drugs ultimately manifested in subject A.McG, (Table 16) who 
was found to have an exceptionally low exit rate of iodide.
Measurement of the 60 minute/20 minute uptake ratio of radio- 
iodide would seem to offer possibilities as a means of checking whether 
the patient is taking the prescribed antithyroid drug. In 97# of the 
measurements during drug therapy this ratio never exceeded 1.38.
The observed values merely reflect the fact that when binding is 
inhibited the slope of the uptake curve is markedly reduced after 20 
minutes. Off antithyroid drugs, however, the uptake ratio was never 
less than 1.42.
As in published work in rats (3), the estimated binding rate of 
pertechnetate was found not to be affected by antithyroid drugs. The 
observed degree of pertechnetate binding, as determined by perchlorate 
discharge, is almost identical to that found by Burke et al (7) in 
thyrotoxic subjects. Compartmental analysis, however, was found to 
overestimate the binding of pertechnetate in the present study. This 
may be a consequence of the arterio/venous approximation used in the
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analysis (Section 3.2), exaggerated because of the small number of 
subjects. Earlier studies in a larger group of subjects (Section 5«4) 
produced a considerably lower mean value for the estimated binding rate 
of pertechnetate.
Unidirectional clearances of iodide and pertechnetate were found 
either to remain virtually constant or to decrease during drug therapy, 
except when plasma TSH was elevated. There was good correlation between 
the unidirectional clearances of the two anions, with that for iodide 
being greater on average by a factor of 1.71. Comparison with earlier 
studies (Section 5.4), where the mean ratio was 3*2$, suggests that the 
relative magnitude of the unidirectional clearances for these two anions 
may be quite variable.
The observed correlation between the 20 minute uptake and 
unidirectional clearance, for both iodide and pertechnetate. Justifies 
the current practice of accepting early thyroidal uptake as an index 
of trapping during drug therapy (2, 116), Furthermore there was good 
correlation between the 20 minute uptakes of the two anions. Thus 
suppression of the 20 minute uptake of either iodide or pertechnetate, 
during drug therapy, reflects suppression of the fundamental trapping 
mechanism of the gland.
One of the most interesting and unique features of the present 
study is the observation of significant initial free uptake of both 
anions, especially when the subjects became clinically euthyroid under 
the action of the antithyroid drug. The initial free uptake in the 
euthyroid state was linearly related to unidirectional clearance. This 
is what would be expected if the initial free uptake were a measure of 
the fraction of the injection bolus that reached the thyroid gland 
(Section 3*3)J & direct relationship being assumed between unidirectional
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clearance and thyroidal blood flow. In the transition from the 
thyrotoxic to the euthyroid state, cardiac output is known to decrease 
(16O-I62), thus a larger fraction of the injected bolus would reach 
the gland initially, provided thyroidal blood flow remained constant.
The fact that initial free uptake was found to increase as the symptoms 
of thyrotoxicosis were suppressed, lends support to this theory.
Initial free uptake of pertechnetate was found to be greater 
than that of iodide, in spite of the fact that the estimated 
unidirectional clearance of the latter was greater* An answer may 
lie in the fact that earlier work, on the affinity of the thyroid gland 
for various anions, suggested that the affinity for pertechnetate 
should be greater than that for iodide (1, 2). However, pertechnetate, 
more so than iodide, is bound to plasma protein (Section 3*1) and 
hence its availability for thyroidal uptake is reduced. Initial free 
uptake may be a better index of the inherent affinity of the gland 
for a specific anion, because it probably reflects circumstances before 
any protein binding has time to be completed. Occurrence of a much 
greater initial free uptake of pertechnetate would explain the 
occasional finding of a 20 minute pertechnetate uptake that exceeds 
that for iodide.
The present findings that the exit rate of pertechnetate is 
greater than that of iodide, and that perchlorate increases the exit 
rate of both anions, are in agreement with the results of other studies 
in man (2, 27, 28, I63). An original observation in the present 
study, however, is that in some cases exit rate may be directly related 
to unidirectional clearance.
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6,3 Short-Term Changes In Iodide Kinetics with Varying Doses of
Carbimazole.
• Patients and methods. Four previously untreated thyrotoxic 
subjects were maintained for consecutive periods of one week on a 
range of carbimazole dosages. In three cases the dosage in the first 
week was 5 mg d"^ , followed by 10, 20, 30 and finally 4-0 mg d“^ during 
the fifth week of study. The final subject received 40 mg d ^ initially 
which was reduced to 30 , 20 and, finally, 10 rag d~^ . None of the 
patients received T3. The plan was to study iodide kinetics before 
carbimazole was given and at the end of each week*s treatment with the 
specified dosages. In one case, however, a study of iodide kinetics 
was made one week after carbimazole was discontinued, rather than before 
drug treatment commenced. Each daily dose of carbimazole was divided 
into two equal portions, given orally at 08,00 and 20.00 hours. The 
kinetic investigations were performed at 14.00 hours on the day of 
study.
Thyroidal uptake of intravenous ^^^I-iodide was studied and 
analysed using the same methods as before (Section 6,2). Each study 
was terminated by an intravenous perchlorate discharge test (Section 3.9). 
An alternative method of estimating binding rate was used which utilises 
the perchlorate discharge results. This was considered necessary 
because kinetic analysis of radioiodide uptake data may produce individual 
estimates of binding rate that are considerably different from the true 
value (Section 6.2),
The method exploits an empirical finding that the fraction of 
radioiodide uptake susceptible to discharge by perchlorate, at any .time, 
is much more dependent on binding rate than on any of the other parameters.
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This almost exclusive dependence on binding rate was elicited by- 
generating a large series of thyroidal uptake curves using the digi-tal 
computer. These curves were constructed for a range of exit and 
binding rates, unidirectional clearances and simulated arterial tracer 
levels. The fraction of uptake that would be discharged by perchlorate 
at any given time was also calculated (Section 2.6).
Figure 6.14 displays the relationship between the dischargeable 
fraction at 60 minutes and binding rate. The curve is independent of 
all parameters except for some dependence on the exit rate of iodide 
before and after perchlorate. Thus the solid line in the figure is 
the relationship when these exit rates are set equal to the mean values, 
0.046 and 0,109 minute respectively, in all subjects studied in the 
present work (Table 22), The dotted area includes 95# of all possible 
variations from the mean curve, which were determined from knowledge 
of the 95# range of the observed exit rates before and after perchlorate. 
Clearly, an estimate of binding rate may be obtained by reference to 
that relationship if the dischargeable fraction at 60 minutes is 
determined empirically. Similar relationships for the dischargeable 
fractions at 10 and 30 minutes are displayed in Appendix 2. (In all 
these derivations, perchlorate is assumed not to affect binding 
(Sections 2,6 and 3.8). If binding is taken to be completely inhibited 
after perchlorate is administered, the estimated fractional discharge 
can be shown to be greater. Tfie resulting relationship between 
dischargeable fraction and binding rate would lead to a greater estimate 
of the latter for a given discharge.)
Statistical analysis of the results was performed using the same 
methods as before (Section 5.3).
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Figure 6=14 Relationship between the fraction of radioiodide 
uptake at 60 minutes dischargeable by perchlorate, and binding rate, 
Tlie solid line is the relationship with the exit mtes, before and 
after perchlorate, equal to the mean values O.O46 and 0,109 minute™^ - 
respectively. The dotted area included 95^ of all possible 
variations from the mean relationship.
Results. The time course of thyroidal uptake of radioiodide, 
during treatment with the greatest and least dosages of carbimazole,is 
compared with that in the untreated state in Figure 6.1$. Even at the 
lowest dosage the uptake curve in all subjects can be seen to be 
markedly affected by the antithyroid drug.
Results of the kinetic analyses of uptake and perchlorate discharge 
in each subject are presented in Table 23. These consist of estimates 
of unidirectional clearance, exit rate and binding rate from the 
uptake phase, each with appropriate random errors. Included also are 
the observed perchlorate discharges at 60 minutes. The second estimates 
of iodide binding rate given in the table are those derived from Figure 
6.14, making use of the observed dischargeable fractions. These 
latter estimates are considered to be more reliable than the binding 
rate estimates from compartmental analysis of the uptake phase. The 
variation of free thyroxine index (158) with dosage of carbiraazole is also 
shown.
The results do not demonstrate any consistent effect of carbimazole 
upon unidirectional clearance and exit rate. Changes in these parameters, 
which cannot be explained by random error, did occur but there is 
no clearly recognisable trend. The drug, however, has a marked effect 
on binding rate. At the lowest dosage (5 mg d"*^ ) the binding rate is 
reduced from a value of ^ 0,150 minute” ,^ before treatment, to, an average 
value of 0.021 minute In two subjects, J.J. and C.I., there Is a
slight reiuction in free thyroxine index. Greater dosages of carbimazole 
reduce the binding rate still further, but except in subject J.J., there 
Is no convincing change in effectiveness over the range 10-40 mg d” .^
In subject J.J. however, the binding rate continues to decrease, so much
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Figure 6>15 Variatioa of thyroidal uptake of radioiodide with 
time in thyrotoxic subjects on two different dosages of carbimazole. 
The solid lines are the best«fit curves during the uptalce and 
perchlorate discharge phases.
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so thatthere is biochemical evidence of hypothyroidism towards the 
end of the study.
Exit rate could not be estimated in subject M.W, when the 
lower dosages of carbimazole were being taken. However, as can be 
seen, that parameter was found eventually to have an exceptionally low 
value - considerably lower than the estimated binding rates for 
carbimazole dosages of 5-10 mg d““^. In these circumstances, problems 
with the compartmental analysis are to be expected (Section 3*7).
A greater problem, however, as far as response to therapy is 
concerned, is the effect of a low exit rate upon the effective clearance 
of iodide. This is shown by the results given in Table 24, which 
include estimates of the effective clearance of iodide (Section 2,7), 
as a percentage of unidirectional clearance,for each subject. As can 
be seen, the results for patient M.W, are uncharacteristic with effective 
clearance remaining relatively high, even at 40 mg d“^ carbimazole.
That patient responded least, biochemically and clinically, in the 
short-term to antithyroid drug therapy. The variation of effective 
clearance and binding rate, with dosage of carbimazole, is shown in 
Figure 6,16. Evidently there is little to be gained by increasing 
the dosage beyond 10 mg d"^ .
Discussion. Different methods have been used in the past to 
test the effectiveness of various treatment regimes of antithyroid drugs. 
These have included comparative measurements of thyroidal uptake of 
radioiodide, before and after treatment (12, I64), and determinations 
of the degree of binding inhibition by perchlorate or thiocyanate 
discharge studies (165-166). The duration of action and degree of 
binding inhibition of antithyroid drugs have been tested in humans by 
sampling thyroid tissue, and assaying in vitro the fraction of radioiodide
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TABLE 24
EFFECTIVE CLEARANCE OF IODIDE IN THYROTOXIC SUBJECTS ON VARYING 
DOSAŒS OF CARBIMAZOLE
Subject Carbimazole 
dosage 
mg d“l
Effective clearance with 
95^ confidence limits *
$ unidirectional clearance
J.J. 0 75 - 100
5 17.527.0
10 7.122.5
20 1.7&0.8
30 0.820.8
40 0.020.8
G.I. 0 75 - 100
5 15.0*3.9
10 2.921.5
20 1.421.5
1 30 2.921 .5
40 1.421.5
M.W. 0 75 - 100
' 5 75.8212.0
10 57.9213.9
20 42.9215.0
30 38.5*14.4
4P 50.0*15.6
J.McI. 40 11.1*6 .1
30 . 7.724 .3
20 7.724 .3
10 11.126.1
0 75 - 100
^  Based on the mean exit rate and binding rate estimate from the 
perchlorate discharge test.
BINDING  RATE 
(minute'U e  SUBJECT JJ.
O SUBJECT C l .
X  SUBJECT M .W , 
+  SUBJECT J.M^I.
0 * 0 3 0 -
0 *01 5-
EFFECTIVE CLEARANCE 20 4 0
100-
5 0 -
20 4 0
mg Carbimazole per day
Flgrire 6^16 Variation of binding rate, and of effective 
clearance of iodide, with dosage of carbimazole in thyrotoxic 
subjects.
that le organically bound (156), Other workers have used compartment si 
analysis of radioiodide uptake to assess the degree of binding inhibition 
after single doses of drug (50),
The present work was an attmept to quantify the rate of iodide 
organification during the short-term treatment of thyrotoxicosis with 
varying doses of antithyroid drug, and to compare this with biochemical 
and clinical response to therapy. In so doing it was hoped that some 
useful predictions could be made as to the minimum dosage regimes 
necessary, in the long-term, for effective control of the disease. Unlike 
previous work on the problem, all essential aspects of iodide accumulation 
by the thyroid gland were investigated, which was of benefit in 
explaining some observed variability in response to the drug.
The technique that was employed provides an estimate of 
organification rate only over the period of each kinetic investigation. 
This may differ in value from the rate at other times if, as in the 
studies, the drug is given in discrete portions. However, any 
difference in observed response to the various dosages of drug, due 
to this effect, were minimised by performing each kinetic study at 
exactly the same time between the two daily portions of the drug. The 
results, therefore, reflect the relative effectiveness of the various 
drug regimes but the observed estimates of binding rate and effective 
clearance of iodide may not, in fact, be mean values for à given drug 
dosage, (There is some indirect evidence (16?) to suggest that the 
drug level in blood, at the time chosen for the kinetic studies, may be 
a reasonable estimate of the mean daily value.)
Binding of iodide was found to be markedly affected by carbimazole 
even at the lowest dosage of 5 mg d~^ ; the binding- rate being at least 
a factor of 7 less than the value in the untreated state. In two out of
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three cases there was a biochemical response to 5 mg carbimazole.
The lack of biochemical response in the third subject was probably 
due to the effective clearance of iodide not being sufficiently 
suppressed. This in turn was the consequence of a relatively low 
exit rate.
There was no detectable difference in effectiveness of carbimazole 
for dosages in the range lO-y^ O mgd”^ in three out of four cases, as 
borne out by the results of the kinetic analysis and to some extent 
by biochemical response* In the remaining case, binding rate and 
effective clearance both continued to decrease with increasing drug 
dosage. By the end of the period of investigation the subject had 
become biochemically hypothyroid.
These short-tem studies have indicated that dosages of carbimazole 
not exceeding 10 mg d  ^might prove to be successful in controlling 
thyrotoxicosis. The results conflict with earlier less detailed 
work (12) which suggested that dosages of this magnitude would not 
effectively reduce iodide binding. In order to resolve this difficulty, 
response to long-term administration of these lower dosages of 
carbimazole is currently being investigated. The present work, has, 
however, demonstrated the value of detailed kinetic analysis of 
radioiodide uptake in explaining variability of response to antithyroid 
drug therapy.
6,4 Investigation of Binding Defects Following Antithyroid Drug 
Therapy.
Patients and Methods. Perchlorate discharge studies were performed 
in 21 untreated thyrotoxic subjects and in 29 thyrotoxic subjects who 
had completed antithyroid drug therapy. Investigations in the latter
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group were performed at 1 week to 30 months after drug treatment and, at 
the time of study, the subjects were receiving triiodothyronine 
supplements of 80 ug d*"^ .
Twenty-nine of the subjects were in fact originally studied by 
Robertson (27, 130) who used a radioisotope scanning technique to 
measure thyroidal uptake-6f radioiodide (Section 5.2). Perchlorate 
was given orally in a dose of 500 mg, 20 minutes after intravenous 
administration of the tracer, and the study continued for a further 
30 minutes. Administration of *^^Tc-pertechnetate, along with the 
radioiodide, permitted the efficiency of the perchlorate to be 
verified. More rigorous statistical analysis is applied here to the 
results of these studies.
The remaining subjects were investigated using either an uptake 
counter (Section 4*2) or gamma camera (Section 4*3) to measure thyroidal 
uptake of intravenous radioiodide. Perchlorate was given intravenously 
as sodium perchlorate in a dose of 300 mg (Section 3.8), 30-60 minutes 
after the tracer. Each study was continued for a further 30 minutes 
after the perchlorate was administered.
Particular attention was paid to the statistical testing of 
uptake variations after perchlorate. The method that was finally 
adopted consisted of performing a linear regression on the uptake 
points after perchlorate and evaluating the "t" statistic (80). This 
allowed the significance of negative gradients, i.e. of apparent 
discharge, to be quantified. Discharge was considered to have occurred 
when the significance level was 955^  or greater. More complex curve 
fitting did not improve sensitivity because the amounts discharged 
were low and/or because there were considerable random variations in 
some of the uptake data.
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Repeated studies of iodide kinetics were performed in two drug- 
treated thyrotoxic subjects who were found to have a significant 
discharge. The studies were a follow-up to earlier work on these 
two subjects (85). Thyroid uptake of radioiodide was estimated using 
a gamma camera (Section 4*3) and data were subjected to compartmental 
analysis (Section 3,9). Each study was terminated by an intravenous 
perchlorate discharge test which provided an alternative, more reliable 
estimate of binding rate (Section 6,3),
Results. For more precise analysis of the results, the 
discharge studies are classified as either "early" or "late" (Table 25), 
Included in the first group are those studies where perchlorate was 
given orally at 20 minutes or intravenously at 30 minutes, (The 
simultaneous studies with ^ ^^Tc-pertechnetate revealed that oral 
perchlorate acts within 3-8 minutes. It seemed reasonable, therefore, 
to combine the results of the 20 minute oral and 30 minute intravenous 
perchlorate discharge studies,) The second group comprises the 
remaining studies where perchlorate was given intravenously 5O-6O 
minutes after the tracer.
Out of 15 untreated thyrotoxic subjects who had "early" discharge 
studies, there is only one with significant discharge of radioiodide. 
This amounted to 7.5^1.4 (^se)^ of the uptake just before perchlorate. 
Although there are 3 out of 18 drug—treated subjects with significant 
"early" discharge, the difference between the untreated and drug- 
treated group is not significant by the chi-square test (p>0,3). The 
discharges (-se) in the latter group were 22,8&8.1, 42,2-8 ,4  and 
61,6^5.5^; 12, 3 and 9 months, respectively, after antithyroid drug
therapy. In the last two cases, however, no discharge was found in
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atudies 7-8 months later.
The "late" discharge studies reveal no significant difference 
(p>0,8) between the frequency of discharge in untreated thyrotoxic 
and drug-treated thyrotoxic subjects after therapy. None of the 
6 untreated cases manifested significant discharge of radioiodide.
Two out of 11 subjects in the drug treated group manifested significant 
discharges; 74.4*1.7 and 12.1^1.9 (6se)%, 19 and 30 months respectively 
after drug therapy.
These last two cases were, in fact, the subject of detailed 
follow-up studies, . Résulté of the kinetic analyses along with the 
free thyroxine index (158) and 20 minute radioiodide uptake, at the 
time of each study, are presented in Table 26. The second estimate 
of binding rate given in the table is that derived from Figure 6.14, 
using the observed dischargeable fraction. This latter estimate is 
considered to be more reliable than the binding rate estimate fmm 
compartmental analysis of the uptake phase (Section 6.3). Thyroid 
uptake curves for each subject, typical of those observed during the 
follow-up period, are plotted in Figure 6,17.
The discharges manifested by subject J.P, are relatively 
small, with some fluctuation being apparent during the period of study. 
Kinetic analysis of uptake in all studies of that subject suggested the 
existence of an iodide binding rate which is considerably greater than 
the exit rate (Section 3.7). In such circumstances neither parameter 
can be determined by compartmental analysis. Estimates of binding 
rate were, however, obtained from the observed discharges. There is 
probably some increase In binding rate with time but, because of 
relatively large errors, accurate assessment of the increase is difficult. 
Taking the mean value of 0.065 minute"^ and a value of 0,046 minute*"^
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Figure 6.17 Thyroidal uptake curves of radioiodide in 
two thyrotoxic subjects 30-91 months after a first course of 
antithyroid ding therapy.
(Table 22) for the exit rate, it may be calculated that the mean 
effective clearance of iodide (Section 2.7) for subject J.P. is 
approximately 59% of the unidirectional clearance.
Unlike the previous subject, the discharge results for subject 
M.D, are quite variable, ranging from no detectable discharge to a 
maximum discharge of 80,1^ of the uptake before perchlorate. The 
kinetic analyses reveal binding rates which are either much less than 
the exit rate or considerably greater; the range of estimated binding 
rates being 0,002->0.150 minute During the course of follow-up,
the subject became thyrotoxic and received another course of anti- 
thyroid drug therapy. Variable discharge was still, however, observed 
after this further period of treatment. An answer to these 
problematical results was discovered unexpectedly during the last study. 
On that occasion, the subject inadvertently admitted to taking 
carbimazole surreptitiously, and to having done so in the past.
Analysis of a urine sample revealed the presence of the drug.
Discussion. The results reveal no increased incidence of 
dischargeable radioiodide in thyrotoxic subjects who have completed 
antithyroid drug therapy. Earlier findings that there was a greater 
incidence (27) were based on less rigorous statistical testing of the 
observed data.
Three out of 18 drug-treated subjects, in fact, manifested 
significant discharge at 20-30 minutes but in 2 of these there was no 
evidence of a binding defect some months later. The finding of a 
small, but significant, "early" discharge in 1 out of 15 untreated 
thyrotoxic subjects has been used earlier in this thesis to provide 
a lower estimate of the rate of "uninhibited" binding (Section 5,5).
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Follow-up studies in two-drug treated subjects who manifested 
dischargeable radioiodide at 50-60 minutes (85), proved to be of
considerable value. In one case, it was proven that carbimazole was
being taken surreptitiously, which explained the subject's euthyroid
clinical state in spite of a continuing high uptake. The other subject
had a relatively small but persistent binding defect. This resulted 
in the effective clearance of iodide being less than 60^ of the 
unidirectional clearance, compared with a normal value of 75-100%
(Section 5.5). Thus again discrepancy between an elevated uptake, yet 
euthyroid clinical state, was resolved. The presence of Hashlmoto's 
thyroiditis (168) is unlikely because of the absence of circulating 
thyroid antibodies, A small congenital defect in binding (l69) cannot 
be totally excluded, for there was no kinetic analysis nor discharge 
test performed when the presence of thyrotoxicosis was first diagnosed.
In conclusion, it is evident that significant discharge of 
radioiodide may be observed occasionally in untreated thyrotoxic subjects, 
and in subjects who have completed anti thyroid drug therapy. There is 
no clear evidence from the results to suggest that antithyroid drugs 
have a long-term effect on thyroid function. Any observed discharge 
in untreated thyrotoxic subjects is likely to be small. This is 
supported by the work of Gray (28) who found no clear evidence of 
discharge at 10 minutes in 12 untreated thyrotoxic subjects, and of 
Stewart and Murray (170) who studied 11 untreated thyrotoxic subjects 
and found only 2 with a small discharge at 1 hour.
Observation of significant discharge, particularly when it is 
relatively small, may in fact indicate the presence of an underlying 
binding rate which is at the lower limit of the normal range. When a
132 -
large discharge is observed in the drug-treated subject, the present 
experience would suggest that the possibility of the subject continuing 
to take antithyroid drug, after the agreed course of therapy, should 
be thoroughly investigated.
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CHAPTER SEVEN
DIRECT QUANTITATIOH OF lODIHE BINDING IN SUBJECTS WITH
lODINATION DEFECTS
7.1 Introduction
Various defects in the synthesis of thyroid hormone have been 
described (91, 171, 172). One defect, however, i.e. defective 
iodination of tyrosine, lends itself to investigation by iodide tracer 
techniques (173). When that defect is present, varying proportions 
of the tracer remain unbound in the thyroid and so can be discharged 
by pharmacological doses of perchlorate. The defect may have definite 
genetic origins, as in forms of congenital thyroid dysfunction, 
including Pendred's syndrome (9, 174, 175), or may be associated with 
autoimmune thyroiditis (Hashimoto's thyroiditis) (l68, 176), It is 
usual for a goitre to be present in association with clinical or 
subclinical hypothyroidism (9, 177). On rare occasions, the thyroid may 
not be enlarged if the defect is due to impaired response to thyroid 
stimulating hormone (9, 1TB), @r if th® gland is atrophied as the end- 
state of Hashimoto's thyroiditis (9). Some degree of impaired iodination 
has been reported in cases of simple non-toxic goitre (28, 168, 169) but 
the possibility exists that there may be genetic factors involved 
(175, 179).
Discharge tests for iodination defects vary widely in method and, 
consequently, in final outcome (2, 28, 81, 170). In some, the
radioiodide is given orally (l68, 169, 176; 180), in others it is given 
intravenously (28, 81, 85, 170, I8l), the perchlorate being given orally 
or intravenously at times ranging from 10 minutes to several hours after 
the tracer. The results have differed widely, especially with regard to
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the frequency of iodination defects in Hashimoto's thyroiditis. Some 
reports suggest that 30-50% of patients with the disease manifest 
significant discharge (91, 176, 182), while more recent studies, in 
which perchlorate was given intravenously at 10 minutes (28), reveal 
an Incidence of nearly 100%,
It is customary to accept that the proportion of radioiodide 
discharged by perchlorate is a measure of the severity of the defect. 
When the iodination process has failed completely, virtually all of the 
tracer can be discharged; in partial failure, as in Hashimoto's 
thyroiditis, only 20-50% can be discharged (173). The binding rate of 
iodide in Hashimoto's thyroiditis and Pendred's syndrome has been 
estimated by Gray (28), but the methods used were indirect and probably 
erroneous - (Section 1,10). Furthermore, the final results were not 
expressed in terms of the effective clearance of iodide (Section 2,7) 
which is a better indicator of iodine utilisation. Direct measurements 
of radioiodide clearance (Section 1.4) have been made in subjects with 
iodination defects (180, 182, 183). If these are combined with 
estimations of plasma inorganic and protein bound iodine, it is possible 
to determine an index of iodide utilisation (180, 184). However, 
inconsistencies do arise because the slope of the uptake curve, and 
therefore clearance, may change markedly with time and may even become 
negative during the period of observation (34, 180),
The studies reported in this chapter were performed on a group 
of subjects who had varying degrees of iodination defect. Observations 
were made of the uptake of radioiodide by the thyroid gland and of its 
discharge by intravenous sodium perchlorate. Data were analysed on the
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basis of the open three-compartment binding model of the gland 
(Chapter 2), object was to quantitate iodine binding, for the
first time by direct methods, in naturally occurring defective iodination 
and to relate this to clinical and biochemical status. It was 
thought that the technique might provide some guide to suitable 
replacement therapy.
7.2 Patients and Methods
Ten subjects, including 6 members of one family, subjects J.S. 
to MD.S. (the male parent and 5 siblings) in the results table to 
follow, were investigated. Where necessary, thyroid hormone replacement 
therapy was discontinued temporarily for the purpose of the 
investigation.
Studies of the family first began when the only male sibling 
(age 12 years) presented with the characteristic features, including 
retarded skeletal growth, of severe thyroid deficiency. Subsequent 
investigations,revealed that other members of the family manifested 
clinical or subclinical hypothyroidism, i.e. increased plasma levels of 
thyroid stimulating hormone. The male parent had, in fact, developed 
clinical hypothyroidism in adult life. Thyroid antibody tests were
negative in all members of the family* None had a distinctly palpable
goitre, but in one case the presence of a slightly enlarged gland was 
detected by radioisotope imaging. The gland was of normal size in the 
other members of the family.
The remaining 4 subjects consisted of one with simple non-toxic 
goitre, one with Hashimoto's thyroiditis (confirmed by positive thyroid 
antibody and perchlorate discharge tests), one with a congenital binding
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defect and goitre, and one with transient pituitary failure. (These 
cases appear in order in the results table to follow), In the last 
subject, two separate studies were performed during the period of 
recovery to normal pituitary function.
Thyroidal uptake was observed for 60 minutes following the 
intravenous administration of either ^^I or ^ ^^I-iodide. After this 
uptake phase, sodium perchlorate (300 mg) was administered intravenously 
and observations continued for a further 30 minutes (Section 3*9).
Uptake measurements were made using either an uptake counter or gamma 
camera by the procedures detailed earlier (Sections 4.2 and 4.3)»
Venous blood samples were taken at appropriate times (Section 3.9) for 
estimation of plasma radioactivity,
A standard procedure was adopted for analysis of the data 
(Section 3.9). This provided estimates of the various parameters of 
the open three-compai'tment binding model of the thyroid gland. The 
perchloi^te discharge phase was also analysed for evaluation of residual 
uptake (Section 2.6). This allowed a more reliable estimate of binding 
rate to be obtained from the proportion of dischargeable radioiodide 
(Section 6.3).
Statistical analysis of the results was performed using the 
methods described in Section 5.3.
7.3 Results
Figure 7.1 shows the variation of thyroid uptake with time in all 
ten subjects. Also displayed is the best-fit uptake curve and the 
variation of bound uptake as determined from the compartmental analysis.
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Figure 7.1 cont'd.
*  estimated from the perchlorate discharge phase.
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Figure 7.1 cont’d.
Thyroid
Uptake 
r% Dose] ^
40. SUBJECT LMCL
o~® Observed Uptake 
—  Bound Uptake
Perchlorate
20
Binding Rate=- 0 -0 0 5  minute
Î—®
30
SUBJECT S.W
6 0
Perchlorate
90
20
Binding Rate= 0-052 minute '
906030 Minutes
Figure 7.1 cont'd
Considerable variation can be seen, from subject to subject, in the 
final slope of the curve during the 60 minute uptake phase. This is 
evidently the result of varying degrees of binding defect, the lower 
the binding rate, the lower the final slope of the uptake curve. In 
most cases there appears to be reasonable agreement between the observed 
residual uptake after perchlorate and the bound uptake estimated by 
the corapartmental analysis.
Results of the digital analysis of the uptake and perchlorate 
discharge phases, along with estimated errors, are presented in Table 27. 
Included also are details of the biochemical status of each subject 
and the 20 minute uptake of radloiodlde. Two estimates of binding 
rate are given, one from analysis of the uptake phase and the other 
from knowledge of the dischargeable fraction at 60 minutes (Figure 6.14) * 
Effective clearance of iodide is expressed as a percentage of the 
unidirectional clearance (Section 2,7) and also in absolute terms 
(ml minute” )^ • The estimate of binding rate from the discharge phase 
was used in the calculation of effective clearance, since it is generally 
more reliable (Section 6,3). This is particularly true in the case 
of patients J.S. and MD.S. when the analysis failed to produce a least 
sum of squares solution that was significantly better than the solution 
with the exit rate equal to zero (Section 3.7).
The unidirectional clearance in the group ranges from 5,6-1352.0 
ml minute” ,^ reflecting a varying response to circulating thyroid 
stimulating hormone (TSH) , which is clearly elevated in 7 cases and at 
the upper limit of the normal range in 2 further cases. Only two 
members (MY.8. and JA.S.) of the family under study showed any positive 
response to elevated TSH output. In each case the unidirectional
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clearance is above the normal range, 14.0-40.6 ml minute”^ (Section 5.4)# 
and in the case of MY.S. the thyroid gland was just detectably enlarged. 
Exit rates in the group are similar to those found previously in normal 
and thyrotoxic subjects (Sections 5.4- and 6.2), and have been included 
In an estimate of the mean value in all patients studied (Table 22).
Observed discharges by perchlorate range widely, from 5.5% to 
98.1% of the uptake at 60 minutes. Binding rates range from 0,000 to 
0,091 minute*"^ . There is reasonable agreement overall between the 
two estimates of binding rate; the observed differences are not 
significant (p > 0,1).
The effective clearance of iodid^ when expressed as a percentage 
of the unidirectional clearance, ranges from 0.0 to 69.4%. In those 
cases where the effective clearance exceeds 60% there is no clear 
biochemical evidence of thyroid disease. In absolute terms, the range 
of effective clearance is 0.0-50.3 ml minute"^. Three of the 4 
subjects with effective clearance at the lower end of the latter range 
(J.S., M,S, and L.McL.) manifest abnormally low levels of both T3 and 
T4. Hormone levels were not measured at the time of investigation in 
the fourth subject (F.McT.) but these were known to be markedly reduced 
several months previously. All four subjects were clinically 
hypothyroid.
The biochemical data shown for patient S.W., who had transient 
pituitary failure, reveal that the radioiodide investigations were 
performed during a time of improving thyroid function, related to the 
restoration of normal pltuitaiy function. This is borne out by the 
results of the kinetic analysis, where both unidirectional clearance
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and binding rate increased significantly with time (p<0,0l).
Figure 7.2 is a plot of effective iodide clearance (ml mlnute“ )^ 
against residual uptake (% dose) after perchlorate. There is highly 
significant linear correlation between these two parameters (p<0,00l).
7.4 Discussion
The fundamental parameters of the iodide accumulation and 
utilisation process have been measured for the first time in subjects 
with widely varying degrees of iodination defect. Tiiis has provided 
quantitative assessment of the binding of iodide and of the extent 
to which the thyroid gland may compensate for the defect. An incidental 
feature of the study was that it provided a further check on the 
reliability of the compartmental analysis technique developed in this 
thesis, there being good agreement between the predictions of the 
analysis and observations after perchlorate.
Binding rates ranged widely, from 0.000 to 0.091 minute"^, but 
in all cases the value was less than the lower limit, 0.150 minute*"^ , 
of the normal range (Section 5.5). The present estimates are 
considerably less than those found by Gray in subjects with iodination 
defects (28). However his method was indirect and was based on the 
doubtful assumption that perchlorate affects binding (Section 1.10 and 
3.8). Furthermore, if the binding were of the order of 0.2 minute‘“^ j 
as his results suggest (Table l), there would have been problems with 
the digital analysis in the present cases. In these circumstances, the 
binding rate would have been considerably greater than the exit rate, 
leading to computational difficulties (Section 3.7).
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Residual 
Uptake 
% Dose
y = 0*375x -f 0-818[r = 0*98]
10-
25 50
Effective Iodide Clearance ml minuterl
Fl^re 7.2 Correlation between the residual uptake of radioiodide, 
after perchlorate at 60 minutes, and the effective clearance of iodide 
in subjects with iodination defects.
The effective clearance of iodide, as a percentage of the 
unidirectional clearance, was always less than 70%, whereas the 
normal range is 75-100% (Section 5*5). There was, however, no 
convincing biochemical evidence of thyroid disease In those cases 
where the effective clearance was 60% or greater. In fact,the only 
evidence of defective iodination was the presence of dischargeable 
uptake which is not usually found unless there is a binding defect 
(Section 6*4). This would suggest that compensatory raechanisms, leading 
to increased output of TSH, are manifestly activated only when the 
effective clearance falls below 60%. Only then, as a rule, will tlyroid 
hormone replacement therapy be deemed necessary.
If, under increased stimulation of the gland, the effective 
clearance of iodide (in ml minute""^ ) fails to achieve a value within the 
normal range, then the output of thyroid hormone is likely to be 
seriously impaired. This was clearly evident in a number of cases 
where the effective clearance was well below the lower limit, 14.0 ml 
minute"*^  (Section 5.4), of the normal range. The achievement of a 
normal value suggests a state of compensated hypothyroidism.
In practice, the effective clearance of iodide may be estimated 
without digital analysis by making use of the correlation between that 
parameter and the residual uptake after perchlorate (Figure 7*2).
This enables the severity of the defect, and therefore appropriate 
replacement therapy, to be determined on the basis of a perchlorate 
discharge test.
The absence of response to endogenous to TSH stimulation, such as 
increased unidirectional clearance and enlargement of the thyroid gland,
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in most of the family included in the study, is unusual. In spite of 
the absence of thyroid antibodies, Hashimoto*s thyroiditis cannot be 
totally excluded because final histological evidence (9, 23) was not 
available at the time of writing of this thesis. Alternatively, 
the basic defect may be one of lack of response to endogenous TSH 
(178). A more complete study of the family is currently being 
undertaken.
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APPENDIX ONE
FIRST PARTIAL DERIVATIVES OF THE SUM OF SQUARES AND
FITTING FUNCTIONS
Derivative of S with respect to
From Section 2,2, the sum of squares function is
8 = y  (üp(tj) - n(tj))2 A
i
where the fitting function is given by 
U(t) = C F(t)' + TJy(T) H(t) * Ug(T)
Thus
= - . y <à s/àKjp  a  (ÏÏQ(tj)-ïï(tj)) ( c>u(tj)/àK^p)Aj.
i
Differentiation of the fitting function yields
à ü(t)/à K^p =
^ C A^e "^it (KB-Ki)
(Kipp Kg—Kjj^) Kj^
1=1
— 1 4 3  —
1=1
c A^ e - V  Kp
(Kjp > Kg -K^ )
(K,pp + Kg) 2
(Kjp +• Kg) (Kjp +' Kg -Kj^ )
^(Krp + Kg -Kj)
C Aie -(%!? + (%?? +
(E?? ^  Kg - Kj)
1=1
(t - T)
TK^ + Kg - kJ
Eb
(K^ 4- Kg) 2
KB (t - T)
Kb
TP ^ (^p ^ *"
%(T)e (t-T) %
(^p ■*" Kg)
^ - (t - T)
Kpp + Kg
- \(T) Kg
Derivative of S with respect to Kg
The procedure is the same as that for the parameter except that
c)U(t)/0Kg =
C A^e -Kit
(Kpp + Kg -Ki)
1=1
Kb - 1_______
Ki(K^ p + Kg - K^ y (K^ + Kg - %i)
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Ki
C A^e
(Kipp ^  Kg —
i=l
(Kpp +" Kg)
Kb___________
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KB
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Derivatives of U(t) with respect to C, U (T) and II (T)r B
àu(t)/èüp(T) = H(t)
ùn(t)/ông(T) = 1
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APPENDIX TWO
Figures shoving the relationship between binding rate and the fractional 
discharge of radioiodide at 10 and 30 minutes (Section 6.3).
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